Androgen receptor-mediated gene activation in prostate cancer cells by Makkonen, Harri Tapani

 
 
 
 
 
 
HARRI MAKKONEN 
Androgen Receptor-
Mediated Gene Activation in 
Prostate Cancer Cells 
 
To be presented by permission of the Faculty of Health Sciences, University of Eastern 
Finland for public examination in the Auditorium L21, Snellmania building, University of 
Eastern Finland, on Saturday 18th September 2010, at 12 noon 
 
Publications of the University of Eastern Finland 
 Dissertations in Health Sciences 
19 
 
Institute of Biomedicine 
School of Medicine, Faculty of Health Sciences 
University of Eastern Finland 
Kuopio 
2010 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kopijyvä Oy 
Kuopio, 2010 
 
Editors: 
Professor Veli-Matti Kosma, M.D., Ph.D. 
Department of Pathology, Institute of Clinical Medicine 
School of Medicine, Faculty of Health Sciences 
 
Professor Hannele Turunen, Ph.D. 
Department of Nursing Science 
Faculty of Health Sciences 
 
 
Distribution: 
 
University of Eastern Finland Library / Sales of Publications 
P.O.Box 1627, FI-70211 Kuopio, Finland 
 
http://www.uef.fi/kirjasto 
ISBN: 978-952-61-0173-6 (print) 
ISBN: 978-952-61-0174-3 (pdf) 
ISSN: 1798-5706 (print) 
ISSN: 1798-5714 (pdf) 
ISSNL: 1798-5706 
  
 
 
Author’s address: Institute of Biomedicine, School of Medicine 
    University of Eastern Finland 
    P.O.Box 1627 
    FI-70211 Kuopio, Finland 
 
Supervisors:  Professor Jorma Palvimo, Ph.D. 
    Institute of Biomedicine 
    University of Eastern Finland 
    Kuopio, Finland 
 
    Docent Sami Väisänen, Ph.D. 
    Department of Biosciences 
    University of Eastern Finland 
    Kuopio, Finland 
 
Reviewers:   Professor Pirkko Härkönen, M.D., Ph.D. 
    Institute of Biomedicine 
    University of Turku 
    Turku, Finland 
 
    Professor Jukka Hakkola, M.D., Ph.D. 
    Department of Pharmacology and Toxicology 
    University of Oulu 
    Oulu, Finland 
 
Opponent:   Docent Pekka Kallio, Ph.D. 
    Orion Pharma 
    Turku, Finland 
  
 
 
 
V 
 
Makkonen, Harri Tapani. Androgen receptor-mediated gene activation in prostate cancer cells. 
Publications of the University of Eastern Finland. Dissertations in Health Sciences 19. 2010. 84 p. 
ISBN: 978-952-61-0173-6 (print) 
ISBN: 978-952-61-0174-3 (pdf) 
ISSN: 1798-5706 (print) 
ISSN: 1798-5714 (pdf) 
ISSNL: 1798-5706 
 
ABSTRACT 
Androgens, testosterone and 5α-dihydrotestosterone are responsible for the male 
phenotype and sexual characteristics. The effects of androgens are mediated by a specific 
nuclear receptor referred to as the androgen receptor (AR). Androgen-bound AR is 
localized to the nucleus where it binds to its response elements (AREs) and activates target 
gene transcription. AR-mediated transcription is crucially involved in normal prostate 
development and maintenance as well as in the development of prostate cancer (PC) that is 
the most common cancer in western males. AR-mediated transcription has been studied in 
detail only at the level of a few model genes from which prostate specific antigen (PSA) has 
been the most studied. This study had two main objectives: firstly, to clarify the 
mechanisms of AR-mediated gene regulation at the chromatin level in PC cells and 
secondly, to study the molecular mechanisms of PC and drug resistance of PC cells. In the 
first part, the AR-dependent transcription of two different AR target genes was 
characterized; ETS-like transcription factor 4 (ELK4) was a novel and FK506-binding protein 51 
(FKBP51) a rarely studied AR target gene. It was demonstrated that ELK4 harbors two 
functional AREs in its proximal promoter. Instead, the AREs of FKBP51 are located in distal 
intronic and upstream enhancers. Since the glucocorticoid receptor (GR) shares partly the 
same binding sites with AR, it was decided to compare the regulation of FKBP51 between 
these two receptors. Interestingly, only minor differences in the regulatory mechanisms 
were found. Both receptors brought about similar changes in the chromatin structure and 
covalent histone modifications as well as RNA polymerase II occupancy. The main 
differences were observed in binding affinity and periodicity of AR binding on certain 
AREs/GREs. It was also found that AR, but not GR, could regulate FKBP51’s neighbor gene 
Chromosome 6 open reading frame 81 (C6orf81) due to different receptor binding affinity to the 
closest enhancer region rather than due to differential binding of the insulator protein 
CTCF. The second part of the thesis examined the mechanisms involved in PC 
development and progression as well as the mechanisms of drug resistance. It was shown 
that ELK4 can promote PC cell growth and its expression is elevated during cancer 
progression. By comparing LNCaP and VCaP cells, it was also found that overexpression 
of AR in VCaP cells could affect the function of antiandrogen drugs. In conclusion, this 
dissertation provides new information on AR-mediated gene activation and molecular 
mechanisms of PC progression and drug resistance, which may be applied to development 
of new PC therapies. 
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TIIVISTELMÄ 
Androgeenit, testosteroni ja 5α-dihydrotestosteroni, vastaavat miehisten 
sukupuoliominaisuuksien kehittymisestä. Tumareseptoreihin kuuluva androgeenireseptori 
(AR) välittää androgeenien vaikutuksia elimistössä. Androgeenien sitoutuessa AR:iin 
reseptori-ligandikompleksi siirtyy tumaan, jossa se sitoutuu androgeenivaste-elementteihin 
(ARE) ja sitä kautta aktivoi kohdegeeniensä transkriptiota. Eturauhasen normaali kehitys ja 
toiminnan ylläpito ovat riippuvaisia AR-välitteisestä geeninsäätelystä. AR on mukana 
myös länsimaisten miesten yleisimmän syövän, eturauhassyövän (PC), kehittymisessä. 
AR:n säätelemää transkriptiota on tutkittu yksityiskohtaisesti ainoastaan muutaman geenin 
osalta, joista selvästi tutkituin on eturauhaselle spesifinen antigeeni (PSA). Väitöskirjan 
ensimmäisenä tavoitteena oli tutkia AR-välitteisen geeninsäätelyn mekanismeja 
kromatiinitasolla PC-soluissa. Niitä tutkittiin kahden kohdegeenin avulla, joista ELK4 oli 
uusi ja FKBP51 ennestään vähän tutkittu androgeeneilla säädelty geeni. ELK4:n 
lähisäätelyalueelta löydettiin kaksi ARE:ä, joiden välityksellä AR aktivoi geeniä. Sen sijaan 
FKBP51:n ARE:t sijaitsevat kaukana intronissa ja ylävirran geenien välisellä alueella 
olevissa lisääjäelementeissä. FKBP51:n AR-välitteistä säätelyä verrattiin myös 
glukokortikoidireseptori (GR) -välitteiseen säätelyyn, koska osan GR:n ja AR:n vaste-
elementeistä tiedetään olevan samoja. Säätelymekanismien välillä löytyi ainoastaan pieniä 
eroja; lähinnä reseptorien sitoutumisaffiniteettien ja -aikojen väliltä. Molemmat reseptorit 
aiheuttivat samansuuntaisia muutoksia kromatiinin rakenteessa, histonien kovalenttisissa 
muokkauksissa ja RNA-polymeraasi II:n sijoittumisessa kromatiinille. Huomattiin myös, 
että toisin kuin GR, AR säätelee FKBP51:n viereistä geeniä C6orf81:tä johtuen ennemminkin 
reseptorien erilaisista sitoutumisaffiniteeteista läheisimmälle lisääjäelementille kuin 
eristäjäproteiini CTCF:n erilaisesta sitoutumisesta. Väitöskirjan toisena tavoitteena oli 
tutkia PC:n sekä sen lääkeresistenssin syntyyn liittyviä molekyylitason mekanismeja. 
ELK4:n määrän havaittiin lisääntyvän sitä mukaa, kun PC etenee pahempilaatuiseksi, ja 
että ELK4 edistää PC-solujen kasvua. PC-lääkkeinä käytettyjen antiandrogeenien 
ominaisuuksia verrattiin LNCaP- ja VCaP-soluissa. Tulosten perusteella VCaP-solujen 
AR:n ylituotanto vaikuttaa lääkeaineiden kykyyn estää AR-välitteistä geeninsäätelyä. Tämä 
väitöstutkimus toi täten uutta tietoa AR-välitteisestä geeninsäätelystä sekä PC:n ja 
lääkeresistenssin kehittymisen molekyylitason mekanismeista. Tuloksia voitaneen soveltaa 
uusien androgeenivaikutusten salpaamiskeinojen kehitystyössä. 
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1. Introduction 
The human genome contains approximately 20,000 to 25,000 protein-coding 
genes. In addition, there are thousands of genes expressing non-coding RNAs 
(ncRNA), which are not coding for proteins. However, out of the 3.2 billion 
nucleotides, only 1–2% code for amino acid sequences of proteins (exons). The 
rest of the genome consists of introns, intergenic regions, regulatory regions, 
repetitive sequences, telomeres, non-coding genes, etc. In the post-genomic era, 
the future goal is to understand how genes are regulated, how they are 
connected together, and how the regulation changes for example during aging, 
illness, nutrition, and drug administration. Knowing the gene regulation per se 
is a prerequisite for developing advanced cures for many diseases. 
Gene regulation is a complex event which consists of several simultaneous 
and sequential processes. The chromatin structure has a significant role in 
transcription initiation and therefore the first step in the gene regulation is 
usually local chromatin remodeling. Nuclear proteins that have the capability 
to modify chromatin structure appropriately in response to gene activation or 
repression signals are recruited to the chromatin by activated transcription 
factors (TFs) which regulate the corresponding gene. The final goal in 
transcription initiation is to activate an enzyme synthesizing RNA, an RNA 
polymerase (RNAP), via the recruited coactivators. 
Androgen receptor (AR) is a hormone-inducible TF belonging to the nuclear 
receptor (NR) superfamily, which is the largest family of DNA-binding TFs in 
humans. The natural ligands for AR are the male sex hormones, testosterone 
and 5α-dihydrotestosterone (DHT). Testosterone is produced mainly by testes 
and the more potent DHT in the target tissues. Androgen-bound AR (holo-AR) 
is translocated from the cytosol to the nucleus where it binds to its response 
elements (AREs) or interacts with other sequence-specific transcription factors, 
resulting in activation or repression of gene transcription. Perturbations in AR-
mediated gene regulation are strongly linked to the development of prostate 
cancer (PC). PC is the leading diagnosed cancer and the second leading cancer-
caused death in western males. The search for an efficient therapy for PC will 
depend on careful examination of the mechanisms of AR-mediated gene 
regulation. 
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In this dissertation, the mechanisms of AR-mediated gene activation will be 
discussed at the example of two model genes, ETS-like TF 4 (ELK4) and FK506-
binding protein 51 (FKBP51). In addition, the molecular mechanisms of PC 
development, especially the role of ELK4, will be discussed as well as the 
mechanisms of development of drug resistance in PC. 
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2. Review of literature 
2.1 NUCLEAR ARCHITECTURE 
The nucleus is a membrane-bounded cell organelle containing most of the 
genetic material of the eukaryotic cell. The nuclear envelope is composed of 
two concentric lipid bilayers, the inner and outer nuclear membranes, from 
which the outer membrane is continuous with the endoplasmic reticulum. The 
structure of the envelope is supported by an underlying, fibrous meshwork 
called the nuclear lamina, which is composed of fibrous lamin proteins. The 
nuclear lamina is directly attached to the lipids in the inner nuclear membrane 
as well as to proteins with in the membrane. Special structures called the 
nuclear pore complexes serve as the sole channels through the envelope. 
Macromolecules, such as proteins and RNAs, and small polar compounds can 
travel from the cytoplasm to the nucleus, or vice versa, through these channels. 
In humans, the genetic material, chromatin, is divided into 46 parts called 
chromosomes, which are attached to the nuclear matrix, the major non-
chromatin component of the nucleus. The isolated character of the nucleus is 
responsible for the main differences between prokaryotic and eukaryotic gene 
regulation. Overall, the nuclear architecture is dynamic rather than a stable 
structure and it plays a remarkable role in gene regulation (Lanctôt et al. 2007). 
In the next chapters, the nuclear architecture will be discussed in the context of 
transcriptional regulation. 
2.1.1 Nuclear matrix and subnuclear structures 
The solid component of the nucleus can be divided into the nuclear matrix and 
chromatin. There are also numerous soluble components (nucleoplasm) in the 
nucleus, such as proteins, RNAs, electrolytes, nucleotides, etc. The nuclear 
matrix is a poorly studied structure and it was originally defined as the non-
chromatin structures of the nucleus readily observed in unextracted cells 
under the electron microscope (Fawcett 1966). It is also called nuclear scaffold 
or nucleoskeleton, because it bears some similarities to the cytoskeleton. The 
matrix consists of two separate parts: the nuclear lamina and the internal 
nuclear matrix that are, however, connected. The internal matrix was first 
discovered as RNA containing protein structures called the fibrogranular 
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ribonucleoprotein (RNP) network. In later studies, the functions of the 
substructures of the RNP were resolved. For example, structures called 
perichromatin fibrils were found to be the sites of RNA transcription and the 
interchromatin granule clusters were observed to be involved in RNA splicing 
(Nickerson 2001). The core of the matrix network is formed by 10-nm branched 
filaments, which are composed of A- and B-type lamin and emerin proteins. 
These core filaments are then covered with proteins and RNAs, producing 
rough surface of the filaments and more evident granules (Elcock and Bridger 
2008). The protein composition of the matrix is quite complex and more than 
400 proteins are known to associate with the nuclear matrix (Mika and Rost 
2005). 
The concept of the nuclear matrix is not very clear, and sometimes certain 
special structures within the nucleus, such as nucleolus, nuclear speckles, 
PML-bodies, and Cajal bodies, are counted as parts of the nuclear matrix or at 
least the nuclear matrix is postulated to be involved in the formation of these 
structures (Fig. 1). Nucleoli are prominent structures where the ribosomal 
RNA is transcribed by RNAPI and coupled with the ribosomal proteins 
(Hernandez-Verdun 2006). One function of nuclear speckles is to act as RNA 
splicing factories, whereas Cajal bodies are involved in biogenesis of nuclear 
RNA (Handwerger and Gall 2006). PML-bodies are formed mainly by SP100 
and promyelocytic leukemia (PML) proteins. The exact role of PML-bodies is 
not known, but they have been often linked to tumor suppression, apoptosis, 
transcriptional regulation, and DNA repair (Bernardi and Pandolfi 2007). 
As mentioned above, the chromatin is attached to the nuclear matrix. Each 
chromosome is located in its own chromosomal territory, which is defined by 
the nuclear matrix. The regions of the chromatin bound to the matrix are called 
scaffold/matrix attachment regions (S/MARs). In the human genome, the 
average distance between two S/MARs is about 50 to 200 kb meaning that the 
chromatin forms loops of that length (Eivazova et al. 2009, Linnemann et al. 
2007, Heng et al. 2004). The S/MARs, however, are not distributed evenly, but 
for example, in telomeres at the ends of each chromosome, an S/MAR can be 
found at one kb intervals (Luderus et al. 1996). The loop formation has a 
significant role in gene regulation. One loop usually contains genes that are 
coordinately regulated and thus might share the regulatory regions (Fig. 2). 
S/MAR forms a physical and regulatory boundary between two loops meaning 
that it could function as a kind of insulator. The best known MAR binding 
protein is special AT-rich sequence-binding protein 1 (SATB1), which acts as a 
link between the chromatin and the nuclear matrix (Galande et al. 2007). 
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Interestingly, SATB1 is also known to interact with PML-bodies and to 
regulate transcription (Kumar et al. 2007). In addition, other factors can form 
chromatin loops and function as insulators, but these are not necessarily bound 
to the S/MAR regions, but to specific binding sites. The master insulator 
protein is CCCTC-binding factor (CTCF), which has several other functions as 
well, such as the regulatory function in gene expression by mediating long-
range chromatin interactions (Phillips and Corces 2009, Nunez et al. 2009). The 
relationship between S/MARs and other insulators is poorly understood. 
However, Antes et al. (2001) proposed that S/MARs function as structural 
boundaries and CTCF-binding sites as functional boundaries. Nevertheless, 
the exact relationship between these different regions remains unclear. Even 
though the role of the loops is to isolate the different gene regions from each 
other, the loop structures are dynamic rather than fixed (Galande et al. 2007). 
For example, induction of gene expression can require remodeling of the loop. 
Chromosomal regions containing active genes can even escape from the 
chromosomal territory of the corresponding chromosome. This loop 
remodeling is believed to be an important event in transcriptional regulation 
(Fig. 2) (Fraser and Bickmore 2007). Perturbations in the nuclear organization 
found in several diseases, especially in cancers, are further confirming the 
importance of appropriate internal organization of the nucleus for proper 
cellular function (Elcock and Bridger 2008). In conclusion, the nuclear matrix 
does not only attach the nuclear components together, but it is a dynamic 
structure that has a remarkable role in nuclear functions. 
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Figure 1. The special structures of the nucleus. (Reprinted from Lanctôt et al. 2007 with kind permission of 
Nature Publishing Group.) 
2.1.2 Chromatin organization and structure 
As discussed above, the chromosomes are located in their own nuclear 
territory and are attached to the nuclear matrix, but how are the genes 
localized in the territories? One general concept is that the active, gene-rich 
chromatin (euchromatin) is located toward the nuclear center, whereas the 
inactive and gene-poor chromatin, such as heterochromatin, is mostly located 
near the nuclear lamina and is tightly bound to the nuclear matrix (Kumaran et 
al. 2008).  However, that is not an absolute rule as Finlan et al. (2008) noted that 
the location of a gene at the nuclear periphery is not incompatible with active 
transcription. Moreover, Gilbert et al. (2004) reported that some active genes 
can be found within the large heterochromatin fibers and conversely, inactive 
genes in the euchromatin fibers, suggesting that the predominant chromatin 
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conformation of the fiber does not, however, directly define the activity of all 
genes within the fiber. In the chromosomal territory, genes are also organized 
in a nonrandom fashion. Active genes seem to locate close to the boundary of 
the territory while inactive genes are located in interior regions of the territory 
(Cremer et al. 2001). However, also this rule is something of a generalization, 
since some activated genes are still located in the center of the territory (Mahy 
et al. 2002). Many gene-rich, constantly active gene clusters, such as the major 
histocompatibility complex, are located in the chromatin loops, which have 
escaped from their chromosomal territories to the interchromosomal space 
(Volpi et al. 2000). Enhancer elements, such as β-globin locus control region, 
can promote the escape from the territory (Noodermeer et al. 2008). 
The traditional thinking has been that TFs are attracted to the chromatin 
during transcription. However, a novel concept suggests that TF complexes 
called transcription factories, rather than activated genes, are stationary 
structures that recruit transcribable chromatin (Fig. 2). These factories are 
located in the boundary of the territory and in the interchromosomal space and 
are bound to the nuclear matrix. These factories are rich in RNAP and certain 
TFs and are thus regulating a cluster of genes that are controlled by the same 
stimuli. The driving force that actually moves the chromatin fibers towards the 
factories remains elusive although some explanations have been proposed. For 
example, it has been postulated that RNAP itself would be responsible of 
chromatin retraction (Schneider and Grosschedl 2007). Interestingly, the genes 
regulated by a given transcription factory do not have to be located in the same 
chromosome. Thus, a certain TF binding site from one chromosome can also 
regulate genes which are located in different chromosomes. This type of 
interchromosomal regulation is called in trans regulation, while 
intrachromosomal regulation is called in cis regulation. In addition to 
transcription, also other events, such as DNA replication, occur similarly by 
specific, fixed protein factories through which the chromatin fiber is retracted 
(Göndör and Ohlsson 2009). 
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Figure 2. Chromatin looping and transcription factories. (Reprinted from Fraser and Bickmore 2007 with 
kind permission of Nature Publishing Group.) 
 
Two special structures can be found in the chromosomes. The telomeres are 
regions/structures found at both ends of each chromosome. They are formed 
by several kb of repetitive sequence TTAGGG and specific proteins associated 
with this sequence. The last few hundred bases of the telomeres consist of 
single stranded DNA, which forms a structure called the t-loop. The role of the 
telomeres is to protect the chromosomal ends from degradation. One 
interesting feature of the telomeres is that they become shortened in every 
mitosis cycle. Ultimately, they have completely disappeared, which prevents 
further cell divisions. Certain types of cells, such as stem cells and cancer cells, 
express the enzyme called telomerase, which extends the telomeres and thus 
enables unlimited number of cell divisions (Artandi and DePinho 2010). The 
second special structure is the centromere found at the center of each 
chromosome. It is a region in the chromosome on which a complex directing 
the chromosome segregation is assembled during cell division (Morris and 
Moazed 2007). The complex is called the kinetochore and it connects the 
chromosome and the spindle microtubules (Santaguida and Musacchio 2009). 
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The DNA sequence of the centromere is not conserved, but it contains 
hierarchical arrays of simple sequence, such as the 171-bp repeats of alphoid 
DNA in mammalian cells and the chromatin at the centromere region is 
epigenetically modified, which causes the recruitment and assembly of the 
kinetochore proteins (Bloom and Joglekar 2010). 
The total length of DNA molecules in a single human cell is about two 
meters. One could ask the question, how does something of that length fit into 
the spherical structure whose diameter is in micrometer scale? The answer is 
efficient packing. At the first level of packing, 146 bp of the negatively charged 
DNA is wrapped 1.65 turns around the octameric positively charged globular 
protein complex called the nucleosome. The core of the nucleosome consists of 
two copies of each of the histone proteins called H2A, H2B, H3, and H4. Each 
histone consists of a globular part and N- and C-terminal tails, which are often 
subjected to post-translational modifications (Luger et al. 1997). The average 
density of the nucleosomes is one in every 200 bp meaning that there is 
nucleosome free linker DNA between two nucleosomes which has a length of 
around 60 bp. This level of packing produces a chromatin fiber whose 
diameter is around 10 nm. This type of fiber is usually called beads-on-a-string 
or euchromatin and it has been usually perceived as transcriptionally active 
chromatin. At the next level of the packing, linker histones, such as histone 1 
(H1), bind to the adjacent nucleosomes bringing the nucleosomes nearer to 
each other. This process produces a fiber of diameter of 30 nm. The chromatin 
is then further condensed to produce finally over 10,000-fold compaction in 
comparison to naked DNA. This type of chromatin is called heterochromatin 
and it is usually transcriptionally inactive (Horn and Peterson 2002). In 
addition to histones, the chromatin contains a huge number of nonhistone 
proteins, which are responsible for transcriptional regulation or performance. 
These proteins are called TFs. In transcriptional regulation, the structure of the 
chromatin is usually modified by specific TFs. This type of regulation can also 
be epigenetic and will be discussed below. 
2.1.3 Structure of human genome 
In addition to the 20,000 to 25,000 genes coding for proteins, the human 
genome consists of several other types of DNA sequences. The content of the 
genome can be divided into nonrepetitive and repetitive sequences. For 
example, exons are usually located within nonrepetitive sequences, meaning 
that there is only one copy of the sequence in the haploid genome. In human, 
more than half of the genome consists of repetitive sequence meaning that the 
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sequence is found more than once in the genome. The nonrepetitive portion of 
the genome consists of exons (~1%), introns (~24%) and other intergenic DNA 
(~22%) for example containing regulatory regions. According to these 
percentages, the genes cover only 25% of the genome. The average human 
gene contains 7 exons, which are 145 bp in length and the total length of the 
gene is 27 kb. The repetitive portion of the genome contains transposons (45%), 
large duplications (5%), simple repeats (3%), and pseudogenes (0.1%, ~3000 
copies). The main origin of the repetitive sequences is probably retroviruses, 
but their exact role is not well known. Previously it was thought that the 
repetitive sequence is only “junk DNA”, but the present understanding is that 
it has some functional role for example in gene regulation (International 
Human Genome Sequencing Consortium 2001). Even though the classical 
genes cover only one quarter of human genome, also other regions of the 
genome are transcribed. These ncRNAs could function as epigenetic regulators 
of transcription and will be discussed more extensively in the next chapter 
(The ENCODE Project Consortium 2007). 
2.2 REGULATION OF TRANSCRIPTION 
Gene expression consists of multiple sequential and simultaneous processes. 
First, a gene is transcribed to heterogeneous nuclear RNA (hnRNA), then 
spliced and modified to messenger RNA (mRNA) and finally translated into 
the amino acid sequence of a protein in cytosol or rough endoplasmatic 
reticulum by ribosomes (O’Malley et al. 1977). All of these steps can be 
regulated, but in this chapter the focus will be on regulation of transcription. 
Transcription is regulated by two main mechanisms: by TF binding to specific 
DNA elements and by modification of the chromatin structure. These two 
mechanisms are strictly linked together and actual order of which one is “egg” 
and which one is “chicken” is not clearly known. Some of the factors needed 
for regulation of transcription are heritable and they can be inherited either by 
genetically or epigenetically. The genetic heritability can be defined as 
inherited DNA sequences of the regulatory regions and the epigenetic 
heritability as heritable phenotype changes that do not involve alterations in 
DNA sequence. For example, the epigenetic changes involve DNA 
methylation, histone modifications and ncRNA-based silencing (Bernstein et al. 
2007). In the subsequent section, the TFs and their DNA-binding sites will be 
discussed together as well as the chromatin modifications and other epigenetic 
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factors. Since the role of the chromatin organization and nuclear matrix in gene 
regulation has been described above, this will not be discussed further. 
2.2.1 Transcription factors and DNA-binding sites 
TFs are proteins involved in the initiation of transcription. In humans, over 
2,000 genes code for TFs and they are generally divided into two categories: 
general TFs and other TFs. RNAPs are not counted as TFs, but they are DNA-
dependent RNAP enzymes activated by TFs and are thus discussed in this 
chapter. Many TFs recognize a specific DNA binding sequence; these factors 
are called sequence-specific DNA-binding TFs (Pan et al. 2010). Some factors 
do not bind directly to DNA, but are bound to other TFs. These are usually 
called cofactors or coregulators, or corepressors or coactivators. TFs have 
several functions, such as chromatin modification and RNAP activation. 
Moreover, some of them have enzymatic activity and some can function as 
receptors for internal or external signals (Brivanlou and Darnell 2002). 
2.2.1.1 RNA polymerases 
There are three RNAPs in eukaryotes: I, II, and III. They have typically ~12 
subunits from which three are common for all RNAPs (Young 1991). The genes 
coding for these subunits are referred with letters and numbers to, for example 
like POLR1A, which stands for Polymerase (RNA) I polypeptide A. From the 
gene bank, subunits for RNAPI from A to E, for RNAPII from A to L, and for 
RNAPIII from A to H, can be found (www.ncbi.nml.nih.gov). Each RNAP has 
specific genes for which it transcribes. RNAPI transcribes genes coding for 
ribosomal RNAs 18S and 28S in nucleolus and has actually the most prominent 
RNA synthesis capability in terms of quantity. RNAPIII is responsible for 
transcribing genes coding for ribosomal 5S RNA, transfer RNAs, and other 
small RNAs in nucleoplasm. RNAPII is the most complex RNAP and is 
responsible for transcribing most of the hnRNAs, which are precursors for 
mRNAs coding for proteins (Archambault and Friesen 1993). The largest 
subunit of RNAPII (POLR2A) has a unique C-terminal domain (CTD), which 
has been linked to several functions of RNAPII, such as an interaction with 
DNA and histone displacement during elongation. The CTD consist of 
multiple repeats (~50) of heptameric amino acid sequence (YSPTSPS), whose 
serine and threonine residues can be phosphorylated. The phosphorylation of 
the CTD is the final activating signal for RNAPII to initiate and continue 
transcription. Phosphorylation at serine 5 is needed for transcription initiation, 
while phosphorylation at serine 2 is needed for RNAPII elongation 
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(Buratowski 2009). The role of the phosphorylation at serine 7 is not very well 
characterized, but it has been linked to small nuclear RNA gene expression 
(Chapman et al. 2007, Egloff et al. 2007). 
2.2.1.2 General transcription factors and the core promoter 
General TFs are factors/protein complexes that are needed for RNAP 
recruitment to the core promoter of a gene and for transcription initiation by 
RNAP. In this section, only the factors involved in transcription of RNAPII 
regulated genes will be discussed. The core promoter is defined as a region 
having all the binding sites needed for RNAPII to bind and function (Fig. 3). 
The size of the core promoter is approximately 100 bp and the transcription 
start site (TSS) lies at the center of the core. General TFs and RNAPII together 
constitute the basal transcription apparatus (BTA) needed for every promoter 
to initiate transcription. In transcriptional activation, distal DNA-bound TFs 
interact with and activate the BTA leading to initiation of transcription, so the 
actual regulation of the transcription is mainly done by other TFs rather than 
by general TFs. The core promoter contains few conserved elements from 
which the one at the center is the initiator element (Inr), whose DNA sequence 
can be described as YYANWYY, where Y is either T or C, N is any nucleotide, 
and W is either A or T. The adenosine of the sequence is the actual TSS (+1). 
Approximately 10%–15% of all promoters contain sequence TATAWAAR, 
where R is either A or G, at ~25 bp upstream of the TSS and which is called the 
TATA-box. Usually the promoters, which do not have a TATA-box, contain a 
downstream promoter element (DPE), whose consensus sequence is RGWYVT, 
where V is either A, C, or G, and this being located at ~30 bp downstream from 
the TSS. Other less studied elements have also been found, such as motif ten 
element (MTE) just upstream from DPE. The presence of these elements 
defines the type of transcription initiation. Two-thirds of human promoters 
have a characteristic of disperse initiation and the rest display the 
characteristics of focused initiation. In disperse initiation, the transcription 
starts from many weak TSSs, while in focused initiation, the TSS is strictly 
defined. Promoters having a TATA-box tend to be of the focused type as well 
as highly regulated genes, while constitutively expressed genes are typically of 
the disperse type (Juven-Gershon et al. 2010). 
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Figure 3. The structure of core promoter. Abbreviations are found in the abbreviation list. 
 
Before polymerase can bind to a promoter and start transcription, a protein 
complex called positioning factor needs to bind first on the core promoter. In 
humans, the factor is called TFIID (II subscript stands for RNAPII), which is 
composed of TATA-binding protein (TBP) and several (up to 14) TBP-
associated factors (TAFs). Although the name of the TBP refers to its ability to 
bind TATA-box, TBP or related factors (TRFs) are still needed for promoters 
that are TATA-box-less. The composition of TAFs can vary for example, 
depending on cell type and thus some variant TFIIDs can recognize alternative 
promoters of genes. TBP is essential, especially for RNAPII, to locate 
promoters to bind, because RNAPII does not have any intrinsic promoter 
recognizing property. In TATA-box-less promoters, TAFs recognize elements 
other than a TATA-box, such as Inr or DPE, for positioning the promoters. 
Next, TFIIA joins the complex and activates TBP’s DNA-binding ability by 
removing TAF1 from DNA-binding surface of TBP (Cler et al. 2009). Then TFIIB 
binds both upstream and downstream (elements called BREu and BREd, Fig. 3) 
to TBP determining the polarity of the promoter, i.e. which strand is template 
and which way RNAPII faces. TFIIB actually forms the surface that is 
recognized by RNAPII (Deng and Roberts 2007). For example, TFIIF is 
responsible for recruiting RNAPII to the assembling complex, since it binds 
tightly to RNAPII. It has also helicase activity and it is actually responsible for 
DNA melting in transcription initiation together with TFIIE and TFIIH (Eichner 
et al. 2010). Next these latter two factors join the complex (Tanaka et al. 2009). 
TFIIH has multiple enzymatic activities e.g. it can achieve the phosphorylation 
of serine 5 and 7 of CTD. The serine 5 phosphorylation is needed for the 
release of RNAPII from the core promoter (Achtar et al. 2009). The timing of 
the phosphorylation on serine 7 by CDK7 (a subunit of TFIIH) is not known, 
but it has been suggested that this occurs before transcription initiation (Boeing 
et al. 2010). The initial transcription of many genes is stopped rapidly and the 
RNA formed is degraded. Subsequently, a complex called positive 
transcription elongation factor b (P-TEFb) is recruited which can 
phosphorylate serine 2 of CTD (Lenasi and Barboric 2010). Finally, the actual 
transcription can start and most of the initiation complex factors are 
-40 TSS (+1) +40
BREu BREdTATA Inr MTE DPE
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dissociated from the promoter, except that RNAPII together with the factors 
needed for elongation, i.e. TFIIS complex (Kim et al. 2007). 
2.2.1.3 Coregulators 
As mentioned above, other TFs rather than general TFs regulate the rate of 
transcription. The effects of TFs on transcription need to be mediated in 
someway to the BTA. In some cases, DNA-binding TFs can interact directly 
with the apparatus, but in most cases there are other factors, called 
coregulators, between them. A coregulator can function either as coactivator or 
corepressor depending on its effect on transcription. Coregulators are usually 
recruited to the chromatin by TFs or by other coregulators. However, all of 
them do not interact with the BTA, but instead modify the chromatin structure 
locally. Coregulators can be divided into three categories: covalent modifiers of 
the chromatin, chromatin remodeling complexes, and mediator complexes. 
The best well characterized coregulators are recruited by NRs and thus the 
focus of this section will be on those factors (Rosenfeld et al. 2006, O’Malley 
2007). 
Covalent modifiers of the chromatin possess an enzymatic activity to either 
add or remove small molecules or proteins to or from the bases of the DNA or 
amino acid residues of the histone proteins. In some cases, a coregulator 
neither adds nor removes molecules, but instead changes (isomerizes) the 
structure of its substituent. The inserted or removed compound is either an 
acetyl group (ac), a methyl group (me), ubiquitin (ub), a small ubiquitin-like 
modifier (SUMO), ADP-ribose (ADPr), or phosphate residue (p). The DNA can 
be modified only by methyl group, but the histones can be modified by all the 
substituents (Kouzarides 2007a). In addition to TFs, these cofactors can be 
recruited at the chromatin by other coregulators, such as p160-family 
coactivators that have no or at best only modest, intrinsic histone 
acetyltransferase activity, or by some corepressors, such as nuclear receptor 
corepressor 1 and 2 (NCoR1 and NCoR2) that function as linkers between TF 
and repressive chromatin modifying enzyme (Privalsky 2004). The specific 
effects of the modifications on transcription as well as the specific coregulators 
will be discussed in chapter 2.2.2. 
Chromatin remodeling complexes are usually ATP-dependent enzymes that 
modify the structure, position, or existence of a certain nucleosome. These 
complexes have an important role in regulation of transcription; especially in 
TF binding to its binding element on DNA. Nucleosomes normally inhibit the 
binding, but dissociation (eviction) or moving (sliding) of the nucleosome from 
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its initial position uncovers the binding site and thus enables the binding of a 
TF (Becker and Hörz 2002, Workman 2006, Gutiérrez et al. 2007). The 
complexes are classified into four classes depending on the central ATPase. 
The central ATPase of the switch mating type/sucrose non-fermenting 
(SWI/SNF) complex is either brahma (BRM) or brahma-related gene 1 (BRG1), 
that of the imitation of SWI (ISWI) complex is ISWI-ATPase, that of the mi-
2/nucleosome remodeling deacetylase (Mi-2/NuRD) complex is 
chromodomain-helicase-DNA binding protein (CHD), and that of the INO80 
complex is INO80 (Hogan and Varga-Weisz 2007). In addition to the 
transcription, the above complexes have specific roles also in other functions in 
the nucleus. For example, ISWI plays a role in replication and INO80 in DNA 
repair and chromosome segregation (Farrants 2008, Hur et al. 2010). In contrast 
to the other complexes, the Mi-2/NuRD complex is involved in transcription 
repression and can be defined as corepressor complex, since it has also histone 
deacetylase activity (Gao et al. 2009). In addition, SWI/SNF has a crossactivity 
to other chromatin modifications, since it has a role in DNA demethylation or 
at least its loss causes DNA methylation (Banine et al. 2005). 
As the name suggests, the mediator complex mediates the activation signal 
from a TF to the BTA. It is a large complex composed of ~20 proteins (called 
MEDs or TRAPs) and its total mass is over 1 MDa. It interacts directly with the 
RNAPII, especially with the hypophosphorylated CTD (Chadick and Asturias 
2005). The mediator can recruit TFIIH, TFIIE, and TFIIS to the core promoter by 
interacting directly with these factors. Due to recruitment of TFIIH, it enhances 
the phosphorylation of the CTD and thus activates the transcription initiation 
(Guglielmi et al. 2007, Esnault et al. 2008, Boeing et al. 2010). The 
phosphorylation of the CTD causes dissociation of the mediator, enabling the 
reinitiation of the transcription (Casamassimi and Napoli 2007). The other part 
of the complex is interacting with TFs or other coregulators and the mediator 
can even recruit them to the chromatin. Thus, the mediator is a key factor 
between TFs and the BTA in transcription initiation (Huang et al. 2003). 
2.2.1.4 Sequence-specific DNA-binding transcription factors 
Regulatory DNA can be defined as a DNA sequence involved in the regulation 
of transcription. These regions can be located either in the nonrepetitive or 
repetitive part of the genome, in intergenic or intragenic regions, in exons, 
introns or untranslated regions (UTRs) (Carroll et al. 2006, Wang et al. 2007, 
Bolton et al. 2007). These regions contain specific DNA sequences recognized 
by sequence-specific DNA-binding TFs. These factors, activators or repressors, 
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activate or repress, respectively, transcription of genes by binding to the 
specific binding sites. Depending on the TF, it can either interact with and 
activate directly the BTA or recruit coregulators which can activate or repress 
the BTA or modify chromatin. Nevertheless, most TFs can interact directly and 
via the coregulators with the BTA (Brivanlou and Darnell 2002). Some factors, 
such as CTCF, interact neither directly nor indirectly with the BTA, but are 
rather structural TFs. These factors regulate the chromatin bending or loop 
formation and thus enable the long range interactions between other TFs and 
the BTA (Phillips and Corces 2009). The binding site or a cluster of binding 
sites that recruits activating or repressing TFs is called either an enhancer or a 
silencer, respectively. The location of the enhancer or silencer of a certain gene 
can be from tens of nucleotides to several kbs in either direction from the TSS 
and the orientation of the element does not matter (Carroll et al. 2006, Wang et 
al. 2007, Bolton et al. 2007). 
Sequence-specific DNA-binding TFs can be categorized into several classes 
depending on their properties or activating mechanisms. Brivanlou and 
Darnell (2002) have proposed the following categories for activating TFs: The 
main groups are constitutive and regulatory TFs. Then the regulatory TFs can 
be divided into cell-specific and signal-dependent, and then signal-dependent 
TFs further into steroid receptors (SR), TFs for internal signals, and cell surface 
receptor activated TFs, which can be further divided into two subcategories. 
The constitutive TFs, such as specificity protein 1 (SP1), are expressed 
constantly in all the cell types and they are responsible for the regulation of 
transcription of constitutively active genes, such as tubulin, and the basal 
activity of other genes. The cell-specific TFs, such as GATA-binding protein 1 
(GATA1), are expressed in tissue-specific manner and are involved mostly in 
developmental processes. These factors are mainly regulated by their 
expression rather than external or internal activation signals. As the name 
suggests, the signal dependent TFs, such as AR, are activated by external or 
internal signals. The cell surface receptor dependent TFs are triggered by the 
activation cascade starting from ligand binding to its cell surface receptor. 
Internal signal-dependent TFs, such as p53, are activated by internal signals, 
such as DNA damage in the case of p53. 
SRs is a subclass of endocrine receptors which is one of the subclasses of 
NRs. The superfamily of NRs consists of 48 members and it is the largest 
family of ligand activated transcription factors in humans. One common 
property to all NRs is the lipophilicity of their ligands. The other two 
subclasses of NR are orphans and adopted orphans. The orphans are NRs 
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whose natural ligand does not exist or at least has not been found. The 
adopted orphans are a group of orphans for which the natural ligand was 
found after the receptor had been cloned. The ligand specificity and binding 
affinity is very different between the endocrine and adopted orphan receptors. 
Endocrine receptors are very specific for their ligands, whereas most adopted 
orphans have large ligand binding pockets that decrease the ligand binding 
affinity and specificity (Chawla et al. 2001). In addition, a more sophisticated 
categorizing system, based on the sequence homology of the NRs, has been 
developed, where the receptors are divided into seven groups (0 to VI). In fact, 
the systematic names of the NR genes are based on this group numbering, for 
example AR’s systematic name is NR3C4 indicating that AR belongs into class 
3C of the NRs (Aranda and Pascual 2001). 
2.2.1.5 Androgen and glucocorticoid nuclear receptors 
The SR subfamily includes AR, glucocorticoid receptor (GR), progesterone 
receptor (PR), mineralocorticoid receptor (MR) and two estrogen receptors 
(ERα, ERβ), from which all but the ERs share the same DNA-binding sites, 
albeit specific sites are also found (Huang et al. 2010). The general protein 
structure of SRs is common for all and several structurally distinct domains 
have been identified: the N-terminal domain (NTD), the DNA-binding domain 
(DBD), the ligand-binding domain (LBD), and a hinge region between DBD 
and LBD, which contains the nuclear localization signal (NLS). NTD is not well 
conserved in the SR family, for example the sequence similarity between AR-
NTD and PR-NTD is only 20%. Conversely, the conservation of DBD is very 
high (~80%) between all SRs except for ER-DBD, whose sequence is only 59% 
similar to that of AR. The differences in ER-DBD compared to other SRs can 
thus explain the difference in DNA sequence recognition (Gao et al. 2005, 
Huang et al. 2010). The transactivation function of SRs is mediated mainly by 
two functional regions: activation function 1 and 2 (AF-1, AF-2), which are 
located in the NTD and LBD, respectively. There is a general mechanism to 
explain how SRs function for all SR’s. First, a hydrophobic ligand diffuses 
through the plasma membrane and binds to the SR monomer in the cytosol. 
The ligand binding causes a conformational change in the receptor’s LBD, 
leading to dissociation of the associated chaperone complex, and 
phosphorylation, dimerization and nuclear translocation of the receptor. In the 
nucleus, the receptor dimer binds to its response elements, recruits 
coregulators and then it can activate transcription (Biddie et al. 2010). 
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Androgens are steroid hormones that function via AR and are responsible 
for the development of male sexual characteristics during embryogenesis and 
puberty as well as maintaining them after puberty. Testosterone and DHT are 
the two most potent natural androgens, with testosterone being produced 
mainly by Leydig cells of the testes and DHT locally in target tissues by 5α-
reductase enzyme from testosterone (Gao et al. 2005). In androgen free 
conditions, AR is inactive and is incorporated into the 
chaperone/immunophilin complex in the cytosol. The complex consists of heat 
shock protein 90 (HSP90) as the main chaperone and at least two co-
chaperones: p23 and either immunophilin protein (a protein that binds 
immunosuppressive drugs) FKBP51, FKBP52, or Cyp40, or non-immunophilin 
protein PP5 (Pratt and Toft 1997, Heitzer et al. 2007). 
In response to androgen exposure, by the mechanisms discussed above, the 
receptor homodimer is translocated to the nucleus where it binds to ARE that 
is a prerequisite for AR-mediated transactivation, but not necessarily for AR-
mediated transrepression (Gao et al. 2005). The mechanisms of AR-mediated 
gene repression are less studied than those of gene activation.  However, it 
appears that the transcriptional repression does not require interaction of the 
receptor with specific DNA elements but interference with other sequence-
specific TFs. For example, AR can repress the activity of activator protein 1 
(AP-1) by interfering with its DNA binding (Kallio et al. 1995). Moreover, AR 
can form a complex with RelA (an activating-subunit of nuclear factor κB, 
NFκB), which leads to their mutual inhibition (Palvimo et al. 1996). AR and 
androgens can also have non-genomic actions, for example AR can activate 
mitogen-activated protein kinases (MAPKs) by transcription-independent 
mechanisms and DHT can bind to membrane-associated AR, which leads to 
rapid increase of intracellular calcium concentration (Foradori et al. 2008). The 
consensus sequence of the ARE is AGAACAnnnTGTTCT that is a type of 
inverted repeat separated by three nucleotides (IR3)-element. If that is also the 
consensus sequence of GR, PR, and MR binding elements, how can there be 
genes that are activated only by androgens? Claessens et al. (2001) proposed 
that in addition to palindromic AREs there are also so-called AR specific 
binding elements that are a type of direct repeat separated by three nucleotides 
(DR3). However, the AR specificity is not absolute, since it was recently shown 
that also PR can bind to DR3-type AREs (Denayer et al. 2010). Moreover, recent 
studies have suggested that only 10% of all the human AREs are canonical and 
the rest are more or less noncanonical i.e. non-IR3-type (Wang et al. 2007, 
Verrijdt et al. 2006, Bolton et al. 2007). Irrespective of the type of the element, 
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AR recognizes and binds to the ARE through two tandem zinc fingers (that 
contain regions called P-box and D-box, respectively) formed by eight cysteine 
residues in DBD and by two central Zn2+. The first zinc finger is responsible for 
specific DNA-recognition, whereas the latter one is needed in AR 
homodimerization. The orientation of the AR monomers depends on the type 
of ARE: IR3 element prefers a head-to-head orientation, whereas DR3 prefers a 
head-to-tail orientation (Verrijdt et al. 2003, Gelmann 2002). The binding 
affinity of AR to an ARE certainly depends on the DNA sequence of the half 
sites, but recent studies have indicated that in addition to ARE itself, proximal 
surrounding binding sites for cell-specific TFs play an important role in AR 
binding efficiency. These factors include at least forkhead box A1 (FOXA1), 
GATA2 and OCT1 (Wang et al. 2007, Gao et al. 2003, Jia et al. 2008). 
After DNA binding, AR interacts directly with the components of BTA and 
recruits coregulators, such as p160-family coactivators (steroid receptor 
coactivator 1, 2, or 3; SRC-1,-2, or -3) that facilitate the recruitment of histone 
modification enzymes, such as p300, cAMP response element-binding protein 
(CREB)-binding protein (CBP), p300/CBP-associated factor (P/CAF), 
coactivator-associated arginine methyltransferase 1 (CARM1), chromatin 
remodeling complexes, such as SWI/SNF, the mediator complex, and many 
other proteins (over 150 coregulators are known for AR) that are involved in a 
wide variety of functions, such as in proteasome-mediated protein degradation 
and SUMO modifications (Fig. 4) (Heemers and Tindall 2007). In contrast to 
the other NRs, ligand-independent AF-1 rather than ligand-dependent AF-2 
plays a major role in AR mediated transactivation and thus also the coactivator 
recruitment differs from the others. AR-LBD interacts poorly with the LXXLL-
motif found in many coactivators; instead it interacts with FXXLF-motifs found 
for example in its NTD and in some AR specific coactivators, such as ARA70. 
The coactivators that have the LXXLL-motif interact with the NTD and DBD 
instead of LBD, and in the situations when the coactivator is overexpressed, it 
can interact also with the LBD (He et al. 2002). 
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Figure 4. Simplified model of androgen receptor-mediated transcription activation. L, ligand; P, phosphate 
residue; other abbreviations are found in the abbreviation list. 
 
Glucocorticoids are steroid hormones that can function via both GR and MR 
due to the high similarity of the receptors’ LBD (Sorrells and Sapolsky 2007). 
The most potent natural glucocorticoid is cortisol that is produced by adrenal 
cortex and its production is regulated by hypothalamus and hypophysis 
hormones. Glucocorticoids regulate many genes involved in gluconeogenesis 
as well as in lipid and amino acid metabolism (Heitzer et al. 2007). They also 
negatively regulate immunoreactions and are thus widely used as 
immunosuppressive drugs, for example in astma (De Bosscher and Haegeman 
2009). In addition, glucocorticoids are mediating stress reactions in the body 
and thus they can also regulate mental functions of the brain (Spijker and van 
Rossum 2009). The mechanisms of GR action are very similar to that of AR and 
are thus not discussed further. 
2.2.2 Histone and DNA modifications and epigenetics 
Histones and DNA are naturally strongly bound together due to their opposite 
net charge: DNA is negatively whereas histones are positively charged. 
However, a too strong interaction between these two partners leads to 
chromatin condensation that inhibits TF binding to their binding elements on 
DNA and thus prevents transcription. Hence, in order to obtain the correct 
transcription level of a gene, the chromatin has to be modified so that it will 
decondensate and enable TF binding. These modifications include chromatin 
remodeling as well as covalent modifications of histones, especially the histone 
tails, and DNA (Kouzarides 2007a, Li et al. 2007a). Many of these modifications 
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are linked together, meaning that one modification may be a prerequisite for 
the next. Together these modifications are suggested to form an epigenetic 
code, i.e. a pattern of certain modifications that poses specific effects on 
transcription. For example, the epigenetic marks can form a specific binding 
surface for TF or coregulator (Fuchs et al. 2006, Turner 2007). Since chromatin 
remodeling is discussed above, the focus will be on the covalent modifications. 
The hereditary nature of these modifications will be also discussed as will be 
the ncRNAs as regulators of transcription. 
2.2.2.1 DNA methylation 
DNA methylation is a key chromatin modification linked to gene regulation, 
imprinting, heterochromatin assembly and X-chromosome inactivation. In 
eukaryotes, the DNA methylation occurs only on carbon five of the cytosine 
base that, at least in mouse brain and embryonic cells, can be further converted 
to 5-hydroxymethyl cytosine (Klose and Bird 2006, Tahiliani et al. 2009). In 
most cases, the DNA methylation is linked to transcriptional repression (Klose 
and Bird 2006). The methylation occurs mostly in CpG islands found in 
promoter region of most genes, but there is also some non-CpG methylation. 
The non-CpG methylation is common only in undifferentiated cells, such as 
stem cells and other embryonic cells, and thus seems to be linked to 
pluripotency and differentiation together with 5-hydroxymethyl cytosine 
(Lister et al. 2009, Tahiliani et al. 2009). This modification is strongly linked to 
other chromatin modifications such as histone methylation. The repressive 
property of the modification is, at least in part, mediated by recruitment of 
histone modification enzymes by methyl-CpG-binding proteins (Klose and 
Bird 2006). Recently, dynamic and cyclical methylation of CpG islands of 
transcriptionally active genes have been reported, suggesting that the DNA 
methylation can be relatively dynamic and involved also in active transcription 
(Métivier et al. 2008, Kangaspeska et al. 2008). The process, where one allele of 
the same gene is closed during embryogenesis, is called imprinting. DNA 
methylation is the key modification that mediates this process (Weaver et al. 
2009). Interestingly, also some RNAs can be methylated at the same carbon, 
but the functional importance of that modification remains elusive (Motorin et 
al. 2010). 
The DNA is methylated by the enzymes called DNA methyltransferases 
(DNMTs). They can be classified into two main groups: de novo (DNMT3a and 
DNMT3b) and maintenance DNMTs (DNMT1). The substrate of the de novo 
DNMTs is the CpG islands that are not methylated on either strand, whereas 
22 
 
maintenance DNMTs copy pre-existing methylation patterns onto the new 
DNA strand during DNA replication. The enzymes that can reverse the 
methylation, i.e. DNA demethylases, have not been found, albeit some 
candidates have been proposed, such as methyl-CpG binding domain protein 2 
(MBD2) (Patra et al. 2008). However, the demethylation does occur, and a few 
indirect mechanisms have been postulated, such as DNA repair, where the 
whole methyl-cytosine is removed and replaced with non-methyl cytosine 
(Gehring et al. 2009). A massive active demethylation occurs in early 
embryogenesis, where paternal DNA is demethylated before the first 
replication, suggesting that there must be also direct mechanisms for 
demethylation of DNA (Abdalla et al. 2009). The 5-methylcytosine is converted 
to 5-hydroxymethylcytosine by enzymes called TET1, -2 and -3 (Tahiliani et al. 
2009). 
2.2.2.2 Histone acetylation 
Histones can be acetylated at their lysine residues in a very dynamic fashion 
during transcription. One of the main mechanisms by which acetylation can 
activate transcription is to decrease of the positive charge of the histones and 
thus histone-DNA interactions. The other mechanism for transcriptional 
activation is that the acetylated lysines form a binding surface for many 
coactivator proteins, such as that have a specific chromatin-binding region 
called bromodomain. H2A can be acetylated at lysine 5 (K5) and K9; H2B at 
K5, K12, K15, K20, and K120; H3 at K4, K9, K14, K18, K23, K36, and K56; and 
H4 at K5, K8, K12, K16, and K91 (Wang et al. 2008b, Verdone et al. 2006, 
Kouzarides 2007b). In contrast to the other acetylated lysines, acetylated H3K4 
(H3K4ac) has been linked to heterochromatin assembly and thus to 
transcriptional repression. However, this modification differs from the other 
lysine acetylations in that it is linked to replication rather than to the dynamic 
transcription regulation in interphase cells (Xhemalce and Kouzarides 2010). 
H3K56 is not located in the histone tail, but in the globular part of the H3 and it 
has been reported that acetylation of the residue does not have any effect on 
histone-DNA interaction, but instead it influences chromatin remodeling by 
SWI/SNF complexes (Neumann et al. 2009). The histone acetylation is not 
distributed evenly in the genome, but it is enriched around the TSSs of the 
active or poised, i.e. epigenetically preprogrammed, genes, and thus it can be 
used as an epigenetic marker for locating active genes (Fig. 5) (Li et al. 2007a). 
The histone acetylation occurs by the function of enzymes called histone 
acetyltransferases (HATs) that are usually found in coactivator complexes. In 
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humans, at least 17 HATs have been found of which CBP, p300, and P/CAF are 
best characterized (Allis et al. 2007). The acetylation is reversed by histone 
deacetylases (HDACs) that can be divided into four groups (I-IV): Class I 
consists of HDACs 1, 2, 3, and 8; Class II of HDACs 4, 5, 6, 7, 9, and 10; Class III 
of silent information regulators 1-7 (sirtuin 1-7 or SIRT1-7); and Class IV of 
HDAC11 (de Ruijter et al. 2003, Brandl et al. 2009). HDACs are usually found in 
corepressor complexes such as in Mi2/NuRD complex and mammalian switch-
independent 3 protein (mSin3) complex (Privalsky 2004). 
2.2.2.3 Histone methylation 
Lysine and arginine (R) residues of the histone tails or globular parts of H2B, 
H3, and H4 can be either mono- (K and R), di- (K and R (symmetric or 
asymmetric)), or trimethylated (only K). The specific residues that can be 
modified are H2B’s K5, H3’s R2, K4, R8, K9, R17, R26, K27, K36, and K79, and 
H4’s R3 and K20 (Barski et al. 2007, Kouzarides 2007b). The effect of a given 
modification on transcription depends strongly on the residue being modified, 
the number of methyl groups added, and the location of the modification with 
regard to the gene. The methylated residues that are linked to transcription 
activation are H3K4, H3K9, H3K20, H3K27, H3K36, H3K79, H3R2, H3R17, 
H3R26, and H4R3, and those linked to repression are H3K9, H3K27, H3K36, 
H3K79, and H4K20 (Li et al. 2007a, Barski et al. 2007). Most of the studied 
modifications have been methylations of H3K4, H3K9, H3K27, and H3K36, 
and thus their role in transcription is best known. Trimethylation of H3K4 and, 
to some extent, its dimethylation are enriched around TSSs of the active genes 
together with acetylation of H3 and H4, and thus these modifications are very 
good markers for an active gene (Fig. 5) (Santos-Rosa et al. 2002, Barski et al. 
2007, Wang et al. 2008b, Guenther et al. 2007). In contrast, monomethylation of 
H3K4 is enriched mainly in the enhancer regions (Heintzman et al. 2007). 
Interestingly, monomethylation of H3K9 is enriched also around TSSs of active 
genes, whereas di- and trimethylation of H3K9 are linked to transcriptional 
repression or heterochromatin together with trimethylation of H3K27. In 
heterochromatin formation, heterochromatin protein 1 (HP1) recognizes and 
binds specifically to di- and trimethylated H3K9. The modification is also 
linked to DNA methylation, since a high level of H3K9 trimethylation and the 
absence of H3K4 trimethylation correlate with high levels of DNA methylation 
(Cheng and Blumenthal 2010). The location of H3K9 methylation relative to a 
TSS determines also the role of the modification; methylation of upstream 
region is linked to transcriptional repression and that of downstream region to 
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activation (Li et al. 2007a). Trimethylation of H3K36 can be enriched in the 
body of active genes being even more enriched in exons and 3’ end of the 
genes and thus it can be also involved in RNA splicing. The modification is 
needed for RNAP elongation and it inhibits aberrant transcription initiation by 
recruiting the Rpd3S HDAC complex that deacetylases histones. Rpd3S 
recognize the modification by its chromodomain, which is a common protein 
region for recognizing methylated histones (Kolasinska-Zwierz et al. 2009, Li et 
al. 2007b). Not only is histone methylation very complicated per se, but the fact 
that it is also linked to other modifications of the histones, makes it and the 
whole histone code even more complex to understand. For example 
phosphorylation of H3 threonine 6 (T6) controls demethylation of H3K4 and 
monoubiquitination of H2BK120 is needed for H3K4 and H3K79 methylation 
(Metzger et al. 2010, Lee et al. 2007). Moreover, histone methylation can even 
impose the ligand dependency in NR-mediated gene activation (Garcia-Bassets 
et al. 2007). 
Enzymes that methylate histones are called histone methyltransferases 
(HMTs). In humans, 48 “suppressor of variegation, enhancer of zeste, 
trithorax” (SET)-domain containing HMTs and DOT1L that does not contain 
the SET-domain, have been found. HMTs are specified to methylate certain 
residues. For example, ASH1L catalyzes only the reaction, where H3K4me2 is 
transformed to H3K4me3. HMTs can form complexes either with other 
coactivators or corepressors and thus the role of methylation in transcription is 
very variable. HTMs are also linked to many diseases. For example, 
overexpression of AR coactivator CARM1, which only methylates arginine 
residues, is linked to PC development and a polycomb group (PcG) protein 
EZH2, that maintains undifferentiated state of embryonic stem cells via 
catalyzing trimethylation of H3K27, is linked to many cancers, including 
lymphoma, melanoma, bladder, breast, colorectal, gastric, and PCs (Albert and 
Helin 2010). The histone methylation can be reversed indirectly by active 
histone exchange, by proteolytic removal of the histone amino-termini or by 
conversion of methylarginine to citrulline by peptidylarginine deiminase, or 
directly by enzymes called histone demethylases (HDMs). HDMs can be 
classified into two classes depending on their structure and activation 
mechanisms: lysine-specific demethylases (LSDs) and jumonji-C-terminal 
(JmjC)-domain containing demethylases. The main functional difference 
between these two groups is that only JmjC-domain containing HDMs can 
demethylate trimethylated lysine residues due to the distinct chemistry of the 
enzymatic reaction (Mosammaparast and Shi 2010). LSD1 was the first 
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demethylase identified and it was not found until six years ago (from the time 
of writing this thesis) and it specifically demethylates H3K4me2 and 
H3K4me1, but not H3K4me3 (Shi et al. 2004). JmjC-domain containing 
retinoblastoma binding protein 2 (RBP2) can demethylate H3K4me3 (Klose et 
al. 2007). However, when LSD1 and JMJD2C interact with holo-AR, they 
promote AR-mediated transcription by demethylating di- and trimethylated 
H3K9, respectively (Wissmann et al. 2007). Interestingly, HDAC inhibitors, a 
putative class of anticancer agents, reduce also H3K4 demethylation by LSD1, 
suggesting that HDACs and HDMs may have some functional interplay (Lee et 
al. 2006). This is further confirmation that epigenetic markers and the enzymes 
involved in the marking can function together in an organized fashion rather 
than independently of each other. 
 
 
 
Figure 5. A summary of the effects of histone modifications and histone variants on transcription. (Reprinted 
from Li et al. 2007a with kind permission of Elsevier.) 
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2.2.2.4 Other chromatin modifications and histone variants 
In addition to the above DNA and histone modifications, histone 
phosphorylation, sumoylation, ubiquitination, ADP-ribosylation, proline 
isomerization, arginine deimination, histone variants, and DNA breaks are 
chromatin modifications involved in the regulation of transcription and these 
processes are mediated by specific enzymes that function as coregulators 
(Kouzarides 2007a). 
Serine (S) and threonine residues of the histones can be phosphorylated by 
specific kinases. H3S10p is linked to chromatin condensation as well as to 
transcriptional activation, but the precise mechanisms are not known 
(Johansen and Johansen 2006, Hayashi-Takanaka et al. 2009). H3T11p is 
mediated by protein-kinase-C-related kinase 1 (PRK1) and this is one of the 
essential modifications for AR-mediated transcription, since it accelerates 
demethylation of H3K9 by JMJD2C (Metzger et al. 2008). 
Histone sumoylation is linked to transcriptional repression (Fig. 5) (Shiio 
and Eisenman 2003). At least in yeasts, all of the core histones can be 
sumoylated on specific lysine residues. The sumoylation represses 
transcription by competing with the activating histone modifications at the 
same lysine residues (Nathan et al. 2006). 
Histone monoubiquitination is linked to both transcriptional repression and 
activation (Fig. 5). Only two residues, H2AK119 and H2BK120, have been 
shown to be modified by ubiquitin (Weake and Workman 2008). H2AK119ub 
can repress transcription by inhibiting RNAPII elongation by preventing 
recruitment of elongation factor FACT (Zhou et al. 2008). Deubiquitination of 
H2AK119ub by 2A-DUB deubiquitinase enhances histone acetylation and H1 
dissociation and thus activates transcription (Zhu et al. 2007). H2BK120ub is 
located at transcribed regions of active genes, but it can also be a repressive 
marker for certain genes (Shema et al. 2008, Minsky et al. 2008). 
The function of ADP-ribosylation on transcription is not fully understood. 
The modification can be either of mono or poly type, but only mono-ADP-
ribosylation is linked to transcriptional regulation. Only one residue of all the 
core histones, H2B glutamate 2 (E2), has been found to be modified by mono-
ADP-ribosylation. Instead, many glutamate and arginine residues of linker 
histone H1 and its variants can also be modified. The modification may also 
undergo some interplay with other histone modifications, such as acetylation, 
but its main function is perhaps to be a marker for DNA damage (Hossa et al. 
2006). 
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Proline (P) can exist either in a trans or in cis conformation, with the trans 
being the predominant form (~90%). The structure of a protein can change 
dramatically due to isomerization of proline residues. Proline isomerases are 
enzymes that can change the proline’s conformation in either direction. H3P30 
and H3P38 are known targets for Fpr4 isomerase. The conformation of H3P38 
is important for H3K36 methylation i.e. the methylation can occur only when 
H3P38 is in the trans conformation. Since the trans conformation is the 
predominant form, Fpr4 activity moves the equilibrium towards the cis-
conformation, and thus Frp4 activity inhibits H3K36 methylation and 
transcriptional activity (Nelson et al. 2006). 
In the arginine deimination reaction, arginine is transformed to citrulline by 
a specific enzyme called PADI4. The deimination takes place with non- or 
monomethylated H3R2 and H4R3, but not on dimethylated versions. Thus 
deimination is one of the indirect mechanisms of demethylation and its effect 
on transcription is mostly due to demethylation, with the effect usually being 
repressive (Wang et al. 2004). 
In addition to the canonic histones, depending on the genomic location and 
the activity of the genes, the histones can be replaced with histone variants. All 
of the histones possess variant versions, albeit variant H4 (H4V) exists only in 
trypanosome (a primitive eukaryote), and they all have a specific role in 
chromatin functions (Talbert and Henikoff 2010). In humans, five different H3 
variants have been found: H3.1, H3.2, H3.3, H3t, and CenH3. H3.1 and H3.2 
are canonical replication specific variants and they are commonly found in S-
phase cells, especially in heterochromatin. H3.3 is replication independent and 
is located at the promoters, enhancers and body of active genes that contain 
active histone marks. H3.1, H3.2, and H3.3 can be involved also in epigenetic 
memory. H3t is testis specific and CenH3 centromere specific variant of H3 
(Hake and Allis 2006). H2B has only two variants and both, TH2B and 
H2BFWT, are testis specific. H2A can have six variants: H2A.X, H2A.Z, 
macroH2A, H2A.Bbd, H2AL1,L2, and H2Abd. The function of macroH2A and 
H2A.Bbd is not known and H2AL1,L2 is a testis specific variant. H2A.X and 
H2Abd are known to be linked to the repair of dsDNA breaks. The most 
important H2A variant for transcription is H2A.Z which possesses both 
repressive and active effects on transcription. It is enriched at the boundaries of 
nucleosome free regions, such as TSSs, and facilitates RNAPII recruitment. 
However, the variant is also enriched in heterochromatin, pointing to a role in 
transcriptional repression (Fig. 5) (Talbert and Henikoff 2010). 
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Topoisomerase IIβ (TopoIIβ) is an enzyme that can generate breaks in 
dsDNA. Interestingly, the TopoIIβ mediated dsDNA break is needed for 
transcription initiation together with subsequent poly-ADP-ribose polymerase 
1 (PARP1) DNA repair complex activity. The mechanism to explain how the 
DNA breakage and repair can enhance transcription is based on H1 exchange 
and thus on chromatin conformation changes (Ju et al. 2006, Ju and Rosenfeld 
2006). 
2.2.2.5 Non-coding RNAs 
ncRNAs are transcribed RNAs that are not translated to proteins. Until 
recently, their important roles in transcriptional regulation and epigenetic 
silencing were not appreciated. The gene silencing mechanisms can be 
categorized into two groups: small RNA-directed transcriptional gene 
silencing (TGS) and siRNA-targeted post-transcriptional gene silencing 
(PTGS). In TGS, the gene expression is inhibited before transcription, whereas 
in PTGS, transcription is intact, but translation is inhibited due to degradation 
of the synthesized mRNA. The other fundamental difference between TGS and 
PTGS is that TGS can be heritable, whereas PTGS is mostly transient (Morris 
2009). 
In TGS, ncRNAs are transcribed from the anti-sense strand of the silenced 
gene or its promoter. The RNAs can be either short or long strands. The 
transcription is usually bidirectional, i.e. both the sense (the mRNA) and the 
antisense (the ncRNA) RNAs are transcribed simultaneously. The main 
function of these RNAs is to regulate the expression of the corresponding gene. 
The RNAs targeted to the promoter region hybridized with the target DNA 
sequence, where they recruit a protein called argonaute 1 (Ago-1), which is 
able to recruit histone and DNA modification enzymes, such as HDAC1, 
DNMT3a, and DNMT1. These then evoke increased methylation of H3K9, 
H3K27, and DNA that, for one, silences the gene. If the ncRNA is expressed for 
a long time (3 to 4 days), the epigenetic changes become stable and inheritable. 
If the target sequence of the ncRNA is located at the TSS or at the boundary of 
an exon and intron, Ago-2 instead of Ago-1 mediates the effects such as 
inhibition of RNAPII recruitment or changes in RNA splicing. In PTGS, small 
antisense RNA of the mRNA of gene to be silenced is hybridized with the 
mRNA leading to dicer-mediated mRNA degradation. As mentioned above, 
PTGS is transient, but easy to execute in the laboratory by transfecting the cells 
with small interfering RNAs (siRNAs) (Morris 2009). 
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ncRNAs can also be involved in transcriptional activation. The effect is not 
direct activation, but instead more resembling derepression. Activating 
ncRNAs are targeted against long antisense RNAs that are inhibitory. These 
anti-antisense RNAs decrease epigenetic effects of anti-sense RNAs by some 
unknown mechanism and more mRNAs are translated into proteins (Morris 
2009). Recently, a new class of ncRNAs called enhancer RNAs (eRNAs) has 
been found. The exact role of these RNAs is not clear, but they are thought to 
be necessary for promoter activation of the corresponding gene (Kim et al. 
2010). 
2.2.2.6 Epigenetic inheritance 
After the publication of Charles Darwin’s theory of evolution, according to 
which inherited properties of an individual are not caused by environmental 
factors, but only by natural selection, Jean-Baptiste Lamarck’s theory of 
inheritance of acquired characters was forgotten for many years. Today, it 
looks that both scientists were right. Inheritance of acquired characters is called 
epigenetic inheritance and this consists of all the changes in usage of genetic 
information that can be passed on to the next generation. The epigenetic 
information is represented by the chemical chromatin modifications discussed 
above. 
How are these modification patterns then copied to daughter cells during 
mitosis or meiosis? This question has remained rather an enigma, albeit some 
mechanisms have been proposed. One clear mechanism involves DNA 
methylation by DNMT1, where the enzyme copies the methylation patterns to 
the newly synthesized DNA strand during mitosis. The mechanism on how 
histone modification patterns are copied to the daughter cells is poorly 
understood. However, the mechanism to explain how heterochromatin is 
copied to the daughter chromatin strand has been partly resolved. In the 
mechanism, trimethylated H3K9 recruits HP1 that can recruit histone 
methyltransferases that methylate newly synthesized chromatin strands 
during mitosis (Bernstein et al. 2007, Portin 2009). In addition, histone 
replacement with the variant species by nucleosome remodeling factors during 
replication has been proposed to be one mechanism in epigenetic inheritance 
(Henikoff 2008). 
Altought epigenetic inheritance during simple mitosis is hard to 
understand, it is even more difficult to comprehend the mechanism how the 
epigenetic information is transferred from parents to offspring in multicellular 
organisms. For example, starvation of the father in his childhood may affect 
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also the daughter’s epigenetic profile in metabolic genes, but the mechanisms 
have not been clarified. Possible candidate factors that carry the epigenetic 
memory from one individual to another are small ncRNAs. In fact, these 
ncRNAs may be the main factors mediating all the epigenetic information and 
the chromatin modifications are simply the end points of the action 
(Kouzarides 2007a). However, more studies are needed to clarify the nature of 
ncRNAs and the whole nature of epigenetic inheritance per se. 
2.3 PROSTATE CANCER 
The prostate gland is a male-specific organ that is located around the urethra 
just under the urinary bladder in the pelvic cavity. It produces most of the 
seminal plasma (the cell-less part of the sperm). Androgens, especially DHT, 
and AR are essential for prostate cell proliferation and differentiation during 
embryogenesis and also after birth in puberty, when the prostate differentiates 
to its final form. During adulthood, androgens are responsible for maintaining 
the prostate function. Histologically, the prostate tissue can be divided into 
stroma or connective tissue and glandular ducts. The wall of the glandular 
ducts is formed by simple epithelium that excretes the seminal plasma into the 
lumen of the ducts. The ducts ultimately open into the urethra, through which 
the sperm is transported outside the body during ejaculation. Prostate 
hyperplasia is a very common age-related benign process that causes urination 
problems due to physical pressure on the urethra. However, benign 
hyperplasia can transform into malign prostate adenocarcinoma that is the 
most prevalent form of PC, but the cancer development does not require 
preceding benign hyperplasia. In fact, it is not known for sure whether benign 
hyperplasia is a susceptibility factor for PC. PC is almost invariably androgen-
dependent at its onset, but the androgen-dependency may diminish while the 
cancer progresses (Heinlein and Chang 2004). PC is the most diagnosed cancer 
and second common cancer-related cause of death in western males (Jemal et 
al. 2008). For example in Finland, over 4,000 men (0.16% of male population, 
30.7% of all the male cancers) receive a PC diagnosis every year 
(www.cancer.fi, www.cancerregistry.fi). In addition, many PCs remain 
undiagnosed, because for example from 70–80% of over 80-year old men are 
found to have asymptomatic PC post-mortem, even though the cause of death 
was some other illness (Editors of the physician’s database 2009). Since the risk 
to contract the disease increases with aging and people are living longer, PC 
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has become more and more common on a global level. In addition, life-style 
factors, such as increased intake of saturated fats and red meat and decreased 
intake of vegetables and fruits, are linked to a higher risk for development of 
symptomatic PC (Tomlins et al. 2006b). Thus, the mechanisms contributing to 
this disease are under extensive investigations within efforts to develop novel 
treatments for the disease.  
2.3.1 Diagnostics and therapy 
The symptoms in PC are very similar to that of benign prostate hyperplasia, i.e. 
urination problems including for example weak spout and frequent need for 
urination. In addition to these symptoms, the back surface of the prostate can 
become nodular when palpated through the rectum that is undetectable in 
prostate hyperplasia. The most widely used biomarker for PC is an increased 
level of prostate specific antigen (PSA, also called kallikrein 3 or KLK3) in the 
serum. The degree of the increase correlates well to the disease stage; the levels 
increase while the cancer progresses. PSA is an androgen-regulated gene, 
whose protein product is a serine protease secreted by prostate epithelial cells 
into the glandular ducts, where it degrades the large proteins produced by 
seminal vesicles to prevent coagulation of the sperm. Normally, very low 
levels of PSA can seep into the circulation, but in PC, due to abnormalities of 
the glandular ducts, the passage becomes easier and thus the PSA levels are 
increased in serum (Heinlein and Chang 2004). The diagnosis can be further 
ensured by prostate biopsy and subsequent histological determination, i.e. 
histopathological diagnosis. If the cancer has developed to the metastatic state, 
bone pains can be felt, because the most prevalent metastatic tissue of PC is 
bone, especially the ribs and vertebrae (Editors of the physician’s database 
2009). The grade of PC is determined by a PC-specific scoring system called the 
Gleason score that was originally established in 1966 (Gleason 1966). In the 
technique, a histological sample is graded from 1 to 5 depending on the cell 
differentiation and other growth properties of the tumor. The most common 
and second common growth pattern of the same sample is graded separately 
and the sum of the scores is the final Gleason score (2–10). The higher the 
score, the more aggressive is the cancer (Lotan and Epstein 2010). 
The type of the therapy depends on the disease state, i.e. whether the cancer 
has not spread (is it inside the surrounding capsule of the prostate), locally 
spread, or spread (metastatic). In fact, most PCs are local and asymptomatic 
and that progress very slowly and never spread outside the capsule. Advanced 
cancer, however, spread usually first to the closest lymph nodes via lymphatic 
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vessels and later to the para-aortic nodes. The cancer cells can also spread via 
blood vessels to axial skeleton, especially to lumbar spine (Clarke et al. 2009). 
The strategy of therapies varies depending on the country, and the Finnish 
system is focused below. The cancer that has not spread can be cured by 
radical prostatectomy, where the prostate is removed surgically, or by 
radiation therapy either traditionally through the skin (external) or 
intraprostatically by small radiating granules. The locally spread PC can be 
treated by prostatectomy, external radiation, or androgen deprivation therapy 
that includes chemical or surgical castration, and/or antiandrogen therapy (Fig. 
6). Metastases are treated usually endocrinologically by chemical or surgical 
castration and antiandrogen therapy. Though prostatectomy is powerful 
therapy for PC, it causes many regrettable side-effects, since almost every 
patient becomes impotent and half of them suffer urinary incontinence after 
the operation. In medical castration, gonadotropin-releasing hormone (GnRH)-
analogs are used to lower the cyclical release of GnRH needed for luteinizing 
hormone (LH) excretion from the pituitary gland. LH is a hormone that 
stimulates androgen production by Leydig cells and thus a decline in LH 
decreases also androgen production (Editors of the physician’s database 2009). 
Antiandrogens are either steroidal or non-steroidal AR antagonists. They 
compete with the androgens for binding to the ligand binding pocket of AR 
(Fig. 6). Antagonist-bound AR is unable to recruit coactivators and/or nuclear 
translocation is inhibited, and thus the AR-mediated transcription becomes 
depressed. That leads to inhibition of AR-mediated cell proliferation and even 
apoptosis of the prostate epithelial cells. Unfortunately, the androgen 
deprivation therapy usually fails and the disease becomes reactivated, leading 
to death (Powell et al. 2006). The mechanism of the reactivation will be 
discussed below. Three antiandrogens are used as medicines in Finland and of 
these, only cyproterone acetate (CTA) is a steroidal compound, whereas 
bicalutamide (BIC) (for structures, cf. Fig. 13) and flutamide are non-steroidal 
drugs (Kariaho et al. 2010). CTA is actually a partial agonist, i.e. it has some 
agonistic properties. In addition to competitive inhibition of AR, the second 
effect of CTA on androgen action is inhibition of LH excretion that finally 
decreases androgen production by the testes. BIC and flutamide are pure 
antagonists and of these BIC is more used due to worse side-effects of 
flutamide (Powell et al. 2006). However, the overexpression of AR can convert 
BIC to act as a partial agonist that is one of the possible mechanisms of the PC 
reactivation (Chen et al. 2004). Recently, novel antiandrogens RD162 (Fig. 13) 
and MDV3100 have been developed that can function as an antagonist also in 
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AR-overexpressing cells (Tran et al. 2009, Scher et al. 2010). Non-competitive 
AR inhibitors have also been developed, but none of them is presently in 
clinical use (Jones et al. 2009). In addition to antiandrogens, 5α-reductase 
inhibitors can be used to reduce DHT synthesis in peripheral tissues (Walsh 
2010). 
 
 
 
Figure 6. The strategies in androgen deprivation therapy. (Reprinted from Attar et al. 2009 with kind 
permission of AACR Publications.) 
2.3.2 Molecular mechanisms 
Molecular mechanisms involved in PC have been investigated extensively for 
many decades. Initially, Charles Huggins and Clarence Hodges (1941) showed 
that the PC growth was dependent on androgens. Still today, it is generally 
believed that the dysfunction of AR-mediated gene regulation is a major factor 
in PC development (Heinlein and Chang 2004, Culig et al. 2002). However, an 
excess of androgens does not cause PC in the healthy man, suggesting that 
androgens are not involved in the initial carcinogenesis, but in its late 
progression (Hsing 2001). However, androgens may promote chromosomal 
translocations that lead to overexpression of growth promoting genes (Mani et 
al. 2009). These translocations are believed to be the main promoting factors for 
PC together with concurrent loss of phosphatase and tensin homolog (PTEN). 
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PTEN is a tumor suppressor inactivating v-akt murine thymoma viral 
oncogene homolog 1 (AKT1), i.e. one of the kinases activating cell growth 
(Kumar-Sinha et al. 2008, Sircar et al. 2009, Squire 2009, Xin et al. 2006). The role 
of androgens and AR in PC progression as well as the role of chromosomal 
translocations will be discussed below more extensively. 
2.3.2.1 Chromosomal translocations 
Transmembrane serine protease 2 (TMPRSS2) is an androgen regulated gene that 
is expressed in human prostate, colon, stomach, and salivary gland, and whose 
function is unknown (Lin et al. 1999, Vaarala et al. 2001, Kim et al. 2006). 
Interestingly, five years ago it was found that TMPRSS2 forms recurrent 
fusions with E twenty-six or E26 transformation-specific (ETS) TF genes 
(Tomlins et al. 2005). ETS TFs regulate genes involved in several important 
cellular functions such as growth, apoptosis, development, and differentiation, 
and they can be thus called oncogenes (Oikawa and Yamada 2003). TMPRSS2 
can be fused at least with v-ets erythroblastosis virus E26 oncogene homolog (ERG), 
ets variant 1 (ETV1), ETV4, and ETV5 from which the fusion with ERG is clearly 
the most prevalent (TMPRSS2-ERG is found in over 50% of all the PCs and the 
rest constitute less than 10%) (Tomlins et al. 2005, Tomlins et al. 2006a, 
Helgeson et al. 2008, Kumar-Sinha et al. 2008). In fact, the high prevalence 
makes the TMPRSS2-ERG fusion very unique and an important marker for PC, 
since the fusion is never found in benign prostate hyperplasia (Kumar-Sinha et 
al. 2008). The TMPRSS2-ERG fusion is formed by ~3 Mb (or less) deletion 
between the genes, occasionally by translocation (Yoshimoto et al. 2006, Tu et 
al. 2007, Iljin et al. 2006). The mechanisms of the deletions or translocations are 
not well known, but holo-AR may promote the fusion formation (Mani et al. 
2009). The fusion mRNA contains usually 5’UTR (exon 1) of the TMPRSS2 and 
the whole coding region (exons 4-11) of ERG, resulting in full length ERG 
protein production by translation (Tomlins et al. 2005, Tu et al. 2007). Since 
TMPRSS2 is an androgen-regulated gene and it has AREs in its promoter 
region, the fusion with the ETS genes subjugates them under AR regulation. 
This subjugation leads to overexpression of ETS genes in prostate cells that 
express AR and have high DHT concentration. Unexpectedly, when examined, 
the TMPRSS2-ERG fusion did not enhance PC growth in mice, but instead 
enhanced the invasiveness of cancer cells (Tomlins et al. 2008). Neither vitamin 
D induced TMPRSS2-ERG fusion mRNA nor ERG protein overexpression can 
promote PC growth (Washington and Weigel 2010). In contrary, positive effect 
of the fusion on cell proliferation has been also reported (Wang et al. 2008a).  
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Overexpression of ERG was associated with high expression of HDAC1 and 
low expression of its target genes, suggesting that the fusion can lead to 
epigenetic reprogramming (Iljin et al. 2006). In fact, recently it has been 
reported that overexpression of TMPRSS2-ERG fusion can increase H3K27 
trimethylation of tumor suppressor genes, leading to their downregulation and 
dedifferentiation of the cancer cells (Yu et al. 2010). 
In addition to TMPRSS2, also other genes have been found as 5’-partners in 
ETS-fusions in PCs. For example, these include androgen regulated gene solute 
carrier family 45 member 3 (SLC45A3) and androgen insensitive gene DEAD 
(Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5) that can form fusions with ERG 
(SLC45A3), ETV1 (SLC45A3), ETV4 (DDX5), and ETV5 (SLC45A3) (Han et al. 
2008, Helgeson et al. 2008, Tomlins et al. 2007). The prevalence of these fusions 
is very minimal (1% to 2%) compared to the major fusion TMPRSS2-ERG (over 
50%) (Esgueva et al. 2010, Han et al. 2008). Interestingly, SLC45A3 can form also 
fusion transcripts with ELK4, a member of the ternary complex factor (TCF) 
subfamily of ETS TFs (Maher et al. 2009, Rickman et al. 2009). The mechanism 
of the fusion mRNA formation does not involve any DNA rearrangement, but 
rather other mechanisms such as intergenic trans-splicing. Maher et al. (2009) 
showed that the chance to have any other known fusion transcript that needs 
DNA rearrangement together with SLC45A3-ELK4 expression is low, 
suggesting that they can exclude each other. Rickman et al. (2009) reported, 
however, that there was no true mutually exclusive expression. A detailed 
discussion about SLC45A3-ELK4 chimaeric transcript can be found in the 
“Results and discussion” section. 
2.3.2.2 The role of AR and coregulators in drug resistance 
Most PCs are initially sensitive to androgens. However, androgen deprivation 
does not kill all the cells, since some of them may have developed mechanisms 
that confer resistance to apoptosis. These mechanisms develop in the early 
stage of the carcinogenesis and they include for example overexpression of an 
antiapoptotic protein B-cell CLL/lymphoma 2 (BCL-2) and other mutations in 
cell growth genes (Dong 2006). During the androgen deprivation therapy, 
these surviving cells develop new, circulating androgen-independent 
mechanisms for enhancing their proliferation. These mechanisms lead to drug 
resistance and runaway growth of PC cells and finally to death of the patient 
(Heinlein and Chang 2004). Though the mechanisms are not dependent on 
circulating androgens, the role of AR is still pivotal and AR-mediated 
transcription can be activated in several ways, e.g. mutations in AR including 
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point mutations and trinucleotide repeats, androgen-independent activation of 
AR, intratumoral androgen production, and overexpression of AR coregulators 
and AR itself. In addition, totally AR-independent mechanisms have been 
suggested for drug resistance (Fig. 7) (Bonkhoff and Berges 2010). 
AR contains two trinucleotide repeats, poly-CAG (polyglutamine) and poly-
GGN (polyglycine), in its NTD that vary in the number of repeats. The number 
of the repeats does not usually change via somatic mutations, but it is an 
inherited property. Thus, the number of repeats is a susceptibility factor for 
drug resistance rather than an actual mechanism for its development during 
deprivation therapy. However, the number of polyglutamine repeats 
negatively correlates to AR expression levels and AR-mediated transcription, 
and thus it may be linked to PC. The decrease in AR-mediated transcription by 
long glutamine repeats (the genotype in Kennedy’s disease) is caused, at least 
in part, by worse recruitment of coregulators. In humans, the number of 
repeats varies from 7 to 36 with 22 being the most prevalent in Caucasian 
males. The association of polyglycine with PC has not been extensively studied 
and the results are inconsistent (Choong and Wilson 1998, Palazzolo et al. 2008, 
Heinlein and Chang 2004). Several point mutations of AR are associated with 
PC and drug resistance. They are usually targeted to the LBD of the AR, 
leading to a widened ligand binding pocket that decreases the ligand 
specificity. Thus, other ligands, such as estrogens, progestins and even 
antiandrogens, can bind and activate AR (Gottlieb et al. 2004, Heinlein and 
Chang 2004). For example, over one quarter of hormone-refractory metastatic 
PCs have the point mutation T877A (alanine), which is also found in a lymph 
node PC (LNCaP) cell line (Gaddipati et al. 1994, Veldscholte et al. 1990). 
Interestingly, E231G (glycine) mutation can even initiate the carcinogenesis in 
prostate tissue (Han et al. 2005). In addition to ligand unspecificity, the 
mutations can evoke different recruitment of coregulators by AR and thus 
different gene expression profiles (Brooke et al. 2008). 
AR can also be activated ligand-independently by other pathways, such as 
by several growth factors and inflammation signals (Zhu and Kyprianou 2008, 
Kaarbo et al. 2007). For example, overexpression of HER-2/neu tyrosine kinase 
can modulate the AR-signaling to function under low androgen conditions and 
interleukin 6 (IL-6) can activate AR in a ligand-independent manner (Craft et 
al. 1999, Malinowska et al. 2009). Moreover, several studies have claimed that 
there is an overexpression of AR coregulators as the key factor in the 
development of drug resistance (Golias et al. 2009, Culig et al. 2004, Chmelar et 
al. 2006). For example, overexpression of SRC-1 and SRC-2 in recurrent PCs 
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increased the AR-mediated transcription with physiological concentrations of 
adrenal androgens (Gregory et al. 2001). However, in another study, 
overexpression of AR coregulators could not be observed in clinical samples 
(Linja et al. 2004). Overexpression of the coactivators may promote a prolonged 
AR interaction with AREs that leads to androgen-independent activation of AR 
(Shi et al. 2008). Even though AR is usually the main regulator of PC cell 
growth, AR can be also bypassed by several mechanisms. For example, 
overexpression of ERα can subjugate the growth control of the cells under 
estrogen or progesterone regulation instead of androgens (Bonkhoff and 
Berges 2009). 
Even though androgen depletion therapy decreases blood androgen levels 
almost completely (95%), the levels are decreased only by 50-80% in the 
prostate tissue. Nonetheless, that level of decrease can kill most of the cells, but 
some can still survive. The surviving cells are in some way hypersensitized to 
the low level of androgens, a process that can occur by the mechanisms 
discussed above and/or by AR overexpression (Heinlein and Chang 2004). The 
overexpression can be caused for example by AR gene amplification (Koivisto 
et al. 1997, Gregory et al. 2001, Linja et al. 2001). For example, in a vertebrae PC 
(VCaP) cell line, at least five copies of AR were found leading to 
overexpression of AR (Liu et al. 2008). Interestingly, it has been reported that 
the overexpression can transform the pure antiandrogen BIC to act as an 
agonist, suggesting that the overexpression can directly lead to the 
development of drug resistance (Chen et al. 2004). Moreover, overexpression of 
AR can directly sensitize hormone-refractory cells to low levels of androgens 
that lead to increased AR-mediated transcription (Waltering et al. 2009). The 
sensitizing is facilitated by intratumoral synthesis of androgens that cannot be 
blocked by chemical castration and this further depresses the efficiency of the 
treatments (Mostaghel et al. 2007, Montgomery et al. 2008). 
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Figure 7. The mechanisms on developing castration-resistant prostate cancer (CRPC). (Reprinted from 
Knudsen and Scher 2009 with kind permission of AACR Publications.) 
2.3.3 Animal and cell models 
In addition to prostate development, androgens are also responsible for the 
development of many other male and female organs and after development 
they remain crucial for organ function. Malfunction of AR can cause several 
diseases in addition to PC, i.e. androgen insensitivity syndrome (AIS), 
Kennedy’s disease, and infertility. To study the physiological role of AR and 
androgens, the development of AR knock-out and knock-in animal models is 
crucial and a number of AR knock-out mice have been developed (Kerkhofs et 
al. 2009). Men having AIS have female external sexual characteristics, such as 
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female genitalia including clitoris and blind end vagina, but the internal female 
organs, such as the uterus, are absent. Moreover, the testes are undescended, 
the prostate, vas deferens, epididymis, and seminal vesicle are absent, female-
type breasts are developed and the axillary and pubic hair are absent (Galani et 
al. 2008). Forty years ago, a mouse model having the AIS phenotype was 
described (Lyon and Hawkes 1970). The mice were infertile and their testes 
were small and undescended, suggesting that androgens regulate the 
inguinoscrotal migration. Also several transgenic mice models with a 
ubiquitous knock-out of the AR (ARKO) mirrors the findings about AIS 
phenotype (Yeh et al. 2002, Kerkhofs et al. 2009). Female ARKO mice have also 
been developed. The studies with these mice have been shown that AR plays 
an important role in the normal development and functions of ovaries, uterus 
and breasts in females (Zhou 2009). Interestingly, male ARKO mice have 
impaired skeletal muscle development, whereas female ARKO mice have 
normal muscle function, suggesting that AR and androgens regulate muscle 
growth and strength in males, but not in females (MacLean et al. 2008). Cell-
specific ARKO mice models have also been developed. Sertoli cell-specific 
ARKO mice males show a normal male phenotype, except that the testes are 
smaller and spermatogenesis is impaired, suggesting that androgens are 
essential for Sertoli cell function in spermatogenesis. In addition, Leydig cell 
and peritubular myoid cell-specific ARKO mice exhibited smaller testes, but 
only Leydig cell-specific ARKO mice were infertile. Together these data 
suggest that AR has a pivotal role in male spermatogenesis (Wang et al. 2009b). 
In addition to knock-out models, some interesting knock-in mice have been 
developed. For example, a mouse model for Kennedy’s disease, where the 
number of CAG repeats was increased, displayed spinal and bulbar muscular 
atrophy and loss of fertility (Yu et al. 2006). By changing the second zinc finger 
of AR’s DBD with that of GR’s (specificity affecting AR knock-in (SPARKI)), 
some effect on fertility and reproductive organs could be observed, suggesting 
that AR-specific AREs are important for male fertility, but not for the anabolic 
effects of AR (Schauwaers et al. 2007). 
Transgenic adenocarcinoma of the mouse prostate (TRAMP) model has 
been developed as a way of studying PC. The TRAMP mice have rat probasin 
promoter driving prostate-specific epithelial expression of the simian virus 40 
(SV4O) large T antigen (Skalnik et al. 1991, Greenberg et al. 1995). Large T 
antigen can promote tumorigenesis of many organs by affecting 
retinoblastoma protein (Rb) and p53, the main tumor suppressors of the 
human cells (Sáenz Robles and Pipas 2009). The TRAMP mice develop prostate 
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tumors as early as on age of 10 weeks and represent a very useful animal 
model for studying PC development and progression (Greenberg et al. 1995). 
For example, TRAMP mice were used to study the effect of SRC-3 on PC 
progression and it was found that SRC-3-knock-out TRAMP-mice did not 
develop PC, suggesting that AR coregulators are essential for PC progression 
(Chung et al. 2007). In addition, PC cell lines derived from TRAMP mice have 
been established (Foster et al. 1997). 
Several prostate cell lines have been established (van Bokhoven et al. 2003). 
Many of them are derived from PC metastasis, such as DU145 (brain), PC-3 
(bone), LNCaP (lymph node), VCaP (vertebral body), and DuCaP (dura), but 
some of them are from primary PC, such as 22Rv1 and CWR-R1. The most 
widely used cell line is LNCaP with the T877A mutation in the LBD of AR that 
leads to unspecificity of the ligands (Veldscholte et al. 1990, Kuil and Mulder 
1996, Bohl et al. 2007). VCaP cells overexpress wild-type AR due to AR 
amplification (Korenchuk et al. 2001, Liu et al. 2008). Since VCaP cells have the 
main PC-specific TMPRSS2-ERG gene fusion and AR is overexpressed, VCaP 
cells are a very useful model cell line for PC (Tomlins et al. 2005). 
2.3.4 AR target genes 
All the effects on cellular function by androgens and AR are a consequence of 
altered gene expression of primary and secondary AR target genes. The 
primary target genes are those that AR regulates directly by binding to the 
promoter or the enhancer regions of the gene, whereas secondary target genes 
are not directly regulated by AR binding, but by other TFs activated by AR. 
The secondary target genes need de novo protein synthesis and are thus 
induced later than the primary genes. AR regulates genes involved in several 
cellular functions, such as in stimulating proliferation, inhibition of apoptosis, 
and production of secreted proteases like PSA (Lamont and Tindall 2010). The 
estimated number of protein-coding mRNAs expressed by AR lies somewhere 
around 1,000, but in addition a huge amount of ncRNAs are expressed (Dehm 
and Tindall 2006). Recently, a microarray experiment with LNCaP cells treated 
with R1881, a synthetic AR agonist, showed that most of the affected genes 
were involved in transforming growth factor β (TGFβ) signaling pathway, fatty 
acid metabolism, steroid biosynthesis, or genes with unknown function (Fig. 8) 
(Ngan et al. 2009). Even though several AR target genes have been identified 
with genome-wide technologies, the molecular mechanisms of AR-regulated 
transcription have been traditionally studied only in one model gene, PSA that 
contains two AREs in its proximal promoter and a more distal upstream 
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enhancer region (Cleutjens et al. 1996, Cleutjens et al. 1997, Schuur et al. 1996, 
Jia et al. 2006). Since the mechanisms can vary in a gene- and cell-specific way, 
it is important to study the mechanisms of the AR-mediated transcription in a 
detailed fashion using several AR target genes and cell models. Moreover, the 
disease state of PC, i.e. whether it is androgen-dependent or -independent, can 
alter the pattern of the genes regulated by AR, further pointing out the 
importance of using a repertuare of models (Wang et al. 2009a). A better 
understanding of the complex mechanisms of AR function will hopefully 
facilitate the development of improved treatments for PC. 
 
 
 
Figure 8. The main pathways and examples of specific genes regulated by androgen receptor according to 
data from Ngan et al. 2009. 
AR
TGF -pathwayβ
-  
-  
SMADs
ID3
↓
↑
⇒
↑
 androgen-mediated
cell growth 
Fatty-acid metabolism
- ,  
-  
ACAA1 ACOX3
ACAA2
↑
↓
⇒
β ↑
 peroxisomal branched
-oxidation 
-  KLF5 ↑
Steroid biosynthesis
⇒ ↑ steroid biosynthesis 
42 
 
  
43 
 
3. Aims of the study 
At the beginning of this study, only a few AR target genes had been 
characterized in detail at the chromatin level. As most knowledge about AR-
mediated transcription was based only on studies about PSA regulation, it was 
decided to characterize novel AR target genes and to clarify in more detail the 
mechanisms of AR-mediated transcription. In addition, the molecular 
mechanisms of AR-mediated PC progression were aimed to study. The more 
detailed aims of this study were: 
 
1. To characterize the AR-mediated regulation of ELK4 at chromatin level. 
 
2. To study the role of ELK4 in PC development and progression. 
 
3. To characterize the AR-mediated regulation of FKBP51 at the chromatin 
level. 
 
4. To compare the AR- and GR-mediated regulation of FKBP51. 
 
5. To study the effects of elevated AR expression on target gene responses to 
different ligands by comparing two different cell models. 
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4. Materials and methods 
In this thesis, a wide range of molecular biology methods were used (Table 1). 
Detailed descriptions of the materials and methods can be found in the 
referred original articles and in Table 2. 
 
Table 1. Materials and methods used in this thesis. 
 
Material or Method Original article 
Cell culture I, II, III, IV 
PCR-primers, EMSA-probes and siRNAs I, II, III, IV, Table 2 
Antibodies I, II, III, IV 
DNA constructs I, II, III, IV 
Quantitative reverse-transcriptase PCR (qRT-PCR) I, II, III, IV 
Reporter gene analysis (RGA) I, II, III 
Electrophoretic mobility shift assay (EMSA) I, II 
Western blotting I, II, III, IV 
Chromatin immunoprecipitation (ChIP) I, II, III, IV 
Cell proliferation assay I 
Tissue microarrays I 
 
 
Table 2. Primers used in Fig. 9. 
 
Transcript Forvard 5'-3' Reverse 5'-3' 
ELK4-E1-E2 AGGCTGAGGGCGGAGAGG CCATCATTAGAGGTCCAACAG 
ELK4-E4-E5 CTGTTGCTCCCCTAAGTCCA CCAGCCCAGACAGAGTGAAT 
SLC45A3-E1-E2 GGCGGAACCAGCCTGCAC CTGCTTCGTCTCGGCTCTG 
SLC45A3-E4-E5 CGCCATCTCCCTGGTCTTC CAGTGTCCCCTCGGTATTTG 
SLC45A3-ELK4-E1-E2 GGCGGAACCAGCCTGCAC CCATCATTAGAGGTCCAACAG 
SLC45A3-ELK4-E4-E2 CGCCATCTCCCTGGTCTTC CCATCATTAGAGGTCCAACAG 
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5. Results and discussion 
5.1 ELK4 IS A NOVEL AR TARGET IN PC (I) 
ELK4, also called serum response factor (SRF) accessory protein 1 (SAP-1), is a 
member of the TCF subfamily of ETS domain TFs. The TCF subfamily contains 
also ELK1 and ELK3 (also called NET, SAP-1, ERP). TCFs are activated by 
MAPKs and they regulate immediate early genes, such as c-fos that encodes a 
subunit of AP-1, by binding to a specific DNA element called serum response 
element (SRE) via their ETS-domain (Dalton and Treisman 1992, Buchwalter et 
al. 2004, Shaulian and Karin 2002). They usually form a ternary complex 
together with SRF (Mo et al. 2001), but they can also regulate target gene 
expression without SRF (Yamazaki et al. 2003). TCFs, like all the ETS domain 
TFs, are regulators of cell life and death and thus potential oncogenes, since for 
example blockade of TCF-mediated transcription leads to growth arrest and 
triggers apoptosis (Vickers et al. 2004). TCFs share common features and 
functional redundancy between them is possible, at least between ELK1 and 
ELK4, since knock-out mice had relatively subtle defects (Cesari et al. 2004a, 
Cesari et al. 2004b, Ayadi et al. 2001, Costello et al. 2004). 
Aberrant expressions of ETS genes are strongly linked to PC progression 
(Kumar-Sinha et al. 2008). Together with ERG, ETV1, ETV4, and ETV5 (Kumar-
Sinha et al. 2008), ELK4 has also been shown to be overexpressed in PC 
according to microarray data by Edwards et al. (2005). Due to the potential role 
of ELK4 in PC progression, it was decided to study its role in PC in more detail 
as well as the regulation mechanisms of its gene expression. It was 
hypothesized that ELK4 might be regulated by AR and this formed the starting 
point for this study, i.e. explore its androgen-sensitivity. It was found that 
ELK4 is an androgen regulated gene, whereas other TCFs were unaffected or 
slightly downregulated by R1881. In fact, the downregulation of ELK3 has also 
been shown by other groups (Bolton et al. 2007) and that may be important in 
AR-mediated cell growth, since ELK3 normally represses the expression of c-
fos and thus restricts cell proliferation (van Riggelen et al. 2005). Two putative 
AREs were in the proximal promoter of ELK4 according to in silico analysis. 
The functionality and AR binding capability of putative AREs were confirmed 
by using a number of different methods including electrophoretic mobility 
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assays (EMSA), reporter gene assays (RGA), and chromatin 
immunoprecipitation (ChIP). The more distal ARE2 was shown to be 
important in prostate derived cells, but not in non-prostate cells, whereas more 
proximal ARE1 showed an opposite dependency, suggesting that functionality 
of the AREs is tissue specific. Moreover, a tissue specific TF FOXA1, but not 
GATA2, was shown to be important for the correct function of ARE2 in PC 
cells and the enrichment of FOXA1 to its binding element adjacent to ARE2 
was shown by ChIP analysis. Others have also emphasized the importance of 
FOXA1 for DNA binding of AR in PC cells (Wang et al. 2007, Gao et al. 2003, Jia 
et al. 2008, Mirosevich et al. 2005, Mirosevich et al. 2006), suggesting that tissue-
specific TFs, such as FOXA1, GATA2, and OCT1, define the tissue specific 
expression of AR target genes. 
Transcription variant A or 1 of ELK4 is encoded by five exons, of which the 
first one contains only 5’ UTR. Instead, transcription variant B or 2 is encoded 
by three exons, from which the first two and the beginning of the exon 3 are 
the same as those of variant A (Fig. 9 and 10A). Therefore, to distinguish 
between the two variants in study I, it was necessary to design the qRT-PCR 
primers to the 3’-end of the gene, accurately to exons 4 and 5, and to 2 and 3 of 
variant A and B, respectively. Recently, Rickman et al. (2009) reported that, 
instead of endogenous ELK4, a fusion transcript SLC45A3-ELK4 was 
upregulated by androgens in LNCaP cells. Since the intergenic space between 
ELK4 and SLC45A3 is only ~25 kb and the direction of the genes is the same, 
the possibility of chimaeric transcript formation is increased. The fusion 
transcripts are reported to contain 5’-region of SLC45A3 (typically only exon 1 
or 4) fused to exon 2 of ELK4. The exon 1 of ELK4 and the exon 5 of SLC45A3 
were always absent in the fusion transcripts, suggesting that these exons 
represent normal expression of ELK4 and SLC45A3, respectively. Moreover, 
the exon 1 of ELK4 was also absent in the fusion transcript reported in another 
study (Maher et al. 2009). To re-evaluate and confirm the expression of ELK4 
and SLC45A3-ELK4 in our experimental system, new primers were designed to 
test the expression of the endogenous and fusion transcripts in LNCaP and 
VCaP cells (Table 2). The cells were treated with 10 nM R1881 for 12 h and the 
mRNAs were analyzed by qRT-PCR. In agreement with Rickman et al. (2009), 
androgen induction of the endogenous ELK4 (ELK4-E1-E2) was poor in LNCaP 
cells (1.3-fold) and absent in VCaP cells (1.0-fold) (Fig. 10B,C). Instead, the 
androgen induction of the endogenous SLC45A3 (E1-E2 and E4-E5) was 
detected in both cell lines, but interestingly the inductions were evidently 
higher in LNCaP cells than VCaP cells (E1-E2, 64-fold vs. 2.8-fold; E4-E5, 17-
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fold vs. 2.7-fold). The higher inductions in LNCaP cells than in VCaP cells were 
probably due to their lower basal expression levels. Similarly, Maher et al. 
(2009) and Rickman et al. (2009) observed higher expression of SLC45A3-ELK4 
fusion transcripts in LNCaP cells than in VCaP cells. The androgen inductions 
were also higher in LNCaP cells than VCaP cells (SLC45A3-E1-ELK4-E2, 9.7-
fold vs. 3.4-fold; SLC45A3-E4-ELK4-E2, 47-fold vs. 5.1-fold), suggesting that 
the fusion has a prior oncogenic role in LNCaP cells. According to these results 
and those of Maher et al. (2009), the fusion transcript containing exon 4, but not 
exons 1-3, of SLC45A3 fused to exon 2 of ELK4 is evidently more abundant in 
both cell lines compared to the SLC45A3-E1-ELK4-E2 fusion. Despite the 
apparently androgen-insensitive expression of the normal ELK4, the AREs 
found in the proximal promoter of ELK4 are likely to be involved in the AR-
promoted transcription of the fusion products. However, further studies are 
needed to clarify the precise mechanism how the AR contributes to the 
formation of the fusion transcripts. In fact, the androgen regulation of 
endogenous SLC45A3 has not been investigated at whole locus and chromatin 
level and the AREs mediating the regulation remain unknown. The AREs 
found in ELK4 promoter can also regulate the expression of other transcription 
variants of ELK4 that do not contain the exon 1. Few alternative variants have 
been reported that do not contain the same exon 1 found in variants A and B 
(Fig. 9). In addition, an alternative promoter is found around exon 2, pointing 
to an alternative TSS at the beginning of exon 2 (www.genomatix.de). Together 
these results suggest that the expression of the coding region of ELK4 is 
regulated by androgens. This may occur either directly via the two AREs found 
in the proximal promoter of ELK4, or through other currently unknown AREs 
regulating the SLC45A3 or by a combination of both mechanisms. ChIP deep 
sequencing analyses of AR-binding sites in LNCaP and VCaP cells may at least 
in part help to resolve these questions. 
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Figure 9. Alternative transcription variants of ELK4. In this diagram, variant b corresponds to variant A in 
the main text. This is the main variant of ELK4. Moreover, variant c corresponds to variant B in the main 
text. This variant shares the first two exons with the main variant A, but the exon 3 is longer and exons 4 and 
5 are absent. Other variants are less abundant and are not mentioned in the main text. Open boxes indicate 
UTRs, closed boxes coding sequence and angled lines depict introns. The picture was captured from 
www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html. 
 
In addition to androgen regulation of ELK4, its expression was evaluated in 
different PCs and its effect on PC cell proliferation. Using siRNAs against 
ELK4 it was found that its downregulation attenuated the growth of LNCaP 
cells, suggesting that ELK4 can promote the proliferation of PC cells. 
Interestingly, in tissue microarray experiments as well as in RNA microarrays 
conducted by others (Yu et al. 2004), ELK4 were overexpressed in hormone-
refractory PCs, suggesting that it may have a role in PC progression. In fact, 
the overexpression of c-fos, a target gene of ELK4, can promote the growth of 
androgen-independent PC (Edwards et al. 2004). Another target gene, early 
growth response 1 (EGR1), can enhance the invasiveness of the aggressive 
hormone-refractory PC cells by upregulating human protease-activated 
receptor 1 (HPAR1) (Clarkson et al. 1999, Salah et al. 2007). Recent findings that 
SLC45A3-ELK4 fusion transcripts, which encode the whole coding region of 
ELK4 and thus full length ELK4 protein, are recurrently overexpressed in PCs, 
together with the functional evidence in this thesis, strongly suggest that ELK4 
has a major role in PC progression (Maher et al. 2009, Rickman et al. 2009). 
Moreover, the expression of the fusion transcript can be measured by 
noninvasive assays from the urine, suggesting that the ELK4 can also be used 
as a diagnostic marker for PC (Rickman et al. 2009).  In conclusion, these data 
suggest that ELK4 is a novel androgen regulated gene overexpressed in 
advanced PC that promotes PC proliferation and is thus a potential target for 
PC therapy together with other ETS-domain TFs overexpressed in PC. 
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Figure 10. Chimaeric transcription of SLC45A3 and ELK4. (A) Schematic view of the SLC45A3-ELK4 locus 
and the major chimaeric fusion transcripts reported by Maher et al. (2009) and Rickman et al. (2009). The 
arrow indicates the direction to the end of the long arm (q) of chromosome 1 and the angled arrows depict 
the TSSs of genes. Black vertical boxes indicate the exons of ELK4, grey the exons of SLC45A3, and thickened 
line the gene body. LNCaP (B) or VCaP (C) cells were treated either with vehicle (ethanol) or 10 nM R1881 
for 12 h and the mRNAs of the indicated transcripts (primers in Table 2) were analyzed by qRT-PCR likewise 
in II. Analyzed GAPDH mRNA levels were used to normalize the amounts of total RNA between the 
samples. The results were calculated using the formula 2-(ΔΔCt), where ΔΔCt is ΔCt(R1881)–ΔCt(EtOH), ΔCt is 
Ct(gene X)–Ct(GAPDH) and Ct is the cycle at which the threshold is crossed, and finally the value of ethanol 
treated ELK4-E1-E2 LNCaP-sample was set as one. The number above the bars indicates the ligand 
induction. Columns represent the mean ± SD of three independent experiments. 
5.2 TRANSCRIPTION OF FKBP51 IS REGULATED BY DISTAL ANDROGEN AND 
GLUCOCORTICOID RECEPTOR-BOUND ENHANCERS (II, III) 
Many genes are known to be regulated by androgens and AREs have been 
characterized genome-widely, but the detailed molecular mechanisms on the 
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holo-AR-mediated gene regulation of most genes remain elusive. The genome-
wide NR-binding studies have shown that most of the binding sites are not 
located in upstream promoter, but in introns, exons and downstream regions 
(Bolton et al. 2007, Carrol et al. 2006, Yu et al. 2010). For example, only 4% of 
ER-binding sites are located in 1-kb proximal promoter region of ER target 
genes, suggesting that the traditional textbook model of gene regulation needs 
to be modified (Carrol et al. 2006). However, the genome-wide ChIP 
technologies (ChIP-seq, ChIP-on-chip) and genome-wide expression assays 
(RNA-seq, RNA-microarrays) do not give the final answer to clarifying the 
relationship between individual binding sites and target genes, since those 
assays only assume that the closest binding site is the major regulatory region 
of a certain gene (Barski and Zhao 2009). The best way to study the relations in 
a genome-wide manner is to use assays that determine direct chromatin 
interactions. These include chromatin conformation capture (3C)-based assays, 
such as chromosome conformation capture carbon copy (5C) and chromatin 
interaction analysis using paired-end tag sequencing (ChIA-PET) (Fullwood 
and Ruan 2009). 
FKBP51 is an immunophilin protein that functions as co-chaperone in SR-
chaperone complexes (Pratt and Toft 1997). Even though AR can directly 
interact and form a complex with FKBP51, FKBP52 is more important for AR-
mediated developmental processes during embryogenesis (Yong et al. 2007). 
However, the expression of FKBP51 is increased in PC and it promotes AR-
mediated transcription and PC cell growth, pointing to a role in PC 
progression (Amler et al. 2000, Velasco et al. 2004, Febbo et al. 2005, Periyasamy 
et al. 2010, Ni et al. 2010). Interestingly, in contrast to androgen-mediated 
transcription, the overexpression of FKBP51 negatively correlates to GR and 
PR activity and thus it has been implicated in glucocorticoid and progestin 
resistance (Reynolds et al. 1999, Hubler et al. 2003). These findings suggest that 
the co-chaperone function is SR-dependent. FKBP51 is regulated by androgens, 
glucocorticoids, and progestins (Amler et al. 2000, Vermeer et al. 2003, Hubler 
et al. 2003, Magklara and Smith 2008). Since the expression of FKBP51 is more 
sensitive to depletion of intraprostatic androgens than any other AR target 
gene (Mostaghel et al. 2007), it was hypothesized that FKBP51 would be mainly 
under AR regulation and influence of other DNA-binding TFs plays a 
secondary role in PC cells. Moreover, FKBP51 has been shown to be a very 
sensitive glucocorticoid target gene in lung epithelia cells, suggesting that the 
expression of FKBP51 is, for one, mainly regulated by GR in lung cells 
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(Woodruff et al. 2007). Thus FKBP51 was chosen as a model gene for studying 
AR and GR-mediated transcriptional regulation. 
It was found that FKBP51 is directly, rapidly and strongly induced by R1881 
and dexamethasone (a synthetic GR agonist) in VCaP as well as in LNCaP cells 
and in A549 cells (lung epithelial cancer cells), respectively. The main 
expressed transcript was variant 1 that differs from its 5’-end compared to the 
longer variant 2 (Fig. 11 and Fig. 1 in III). The expression was increased very 
rapidly compared to for example the situation with PSA, whose expression 
increased very slowly in response to androgen treatment and the maximum 
ligand induction was poor compared to that obtained with FKBP51. 
Cycloheximide treatment did not diminish androgen-dependent expression of 
FKBP51, but instead it slightly increased its overall expression probably due to 
some indirect mechanisms. The androgen induction of a classical AR target 
gene PSA was diminished by cycloheximide treatment, which when 
considered together with its slow androgen induction indicates that de novo 
synthesis is needed for full androgen induction of PSA, but not for that of 
FKBP51. These data further supports the concept that FKBP51 is regulated 
mainly by AR or GR and other TFs do not have any major role in its regulation. 
 
 
 
Figure 11. Androgen upregulates FKBP51 transcription variant 1 expression, but not variant 2. The cells 
were treated with the indicated concentrations of synthetic androgen R1881 for 12 h and mRNAs of 
indicated transcription variant were analyzed by RT-qPCR analysis likewise in II and III. Total RNA levels 
between samples were normalized using mRNA levels of GAPDH. The results were calculated using the 
formula 2-(ΔΔCt), where ΔΔCt is ΔCt(R1881)–ΔCt(EtOH), ΔCt is Ct(gene X)–Ct(GAPDH) and Ct is the cycle at 
which the threshold is crossed, and finally the value of ethanol treated variant 1-sample is set as one. 
Columns represent the mean ± SD of three independent experiments. 
 
The rapid and strong androgen-dependency indicates that several 
AREs/GREs are needed for FKBP51 regulation. To that end, the whole FKBP51 
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locus was scanned in silico to find putative AREs. Initially, 13 AREs were 
found, from which all but one was located in the intronic regions of the gene. 
Later, the scan was expanded to more distal 5’ intergenic region and four 
additional AREs were found. The functionality of the AREs was studied by 
cloning ~300-bp regions containing AREs with luciferase reporter gene 
plasmid and their ability to function as AR-regulated enhancers was assessed. 
The region containing two AREs located at ~34 kb (-3) upstream from the TSS 
was shown to have the best functionality in VCaP cells by androgen treatment, 
whereas the region located at ~87 kb downstream that contained also two 
AREs functioned best in A549 cells in response to glucocorticoid treatment 
(Fig. 12A, II, III, data not shown). The GR-responsiveness of the region located 
at ~87 kb downstream has been previously reported as well as its 
responsiveness also to PR and AR (Hubler and Scammell 2004, Magee et al. 
2006). Interestingly, in COS-1 cells that do not express endogenous AR or GR, 
the differences between AR and GR were absent, suggesting that the 
regulatory differences between the receptors are rather caused by cell line 
specific accessory TFs than DNA-binding ability of the receptors per se (Fig. 
12B). Thus, these data suggest that the most functional AREs of FKBP51 are 
IR3-type/non-AR-specific AREs. 
 
 
 
Figure 12. The upstream enhancer of FKBP51 functions in prostate cell-specific way. (A) VCaP or (B) COS-1 
were transfected with reporter construct driven by 5.8-kb PSA promoter (pPSA5.8-LUC), reporter construct 
containing only TATA-box (pTATA-LUC) or different LUC constructs driven by 0.3-kb FKBP51 fragments 
harboring AR enhancers likewise in II and III. For COS-1 (A) analyses, pSG5-hAR was cotransfected with the 
reporter constructs. Cotransfection of pCMVβ and β-galactosidase activity was used for normalization of 
transfection efficiency. The cells were treated with vehicle (EtOH) or 10 nM R1881 for 24 h before harvesting 
the cells for reporter analyses. Results are shown as relative LUC activity, with the activity of pTATA-LUC 
in the absence of R1881 set as 1, and fold inductions of androgen-treated samples in the relation to the 
activity of ethanol-treated samples are shown above the columns. Columns represent the mean ± SD of three 
independent experiments. 
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The in vivo binding of AR and GR was studied in ChIP assays. The binding 
patterns were rather similar between the receptors, but the relative binding 
efficiency between the different regions was different as was the kinetics of the 
binding. The best AR and GR binding was found in the region located at ~87 
kb downstream which together with the previous findings emphasizing the 
importance of the region in SR-mediated regulation of FKBP51 (Hubler and 
Scammell 2004, Magee et al. 2006). The region located at ~34 kb upstream was 
shown to represent the main difference in binding efficiency between the 
receptors, since AR binding to it was equal to that of the region located at ~87 
kb downstream, but the GR binding was only less than half of that value. 
These data further suggest that the region located at ~34 kb upstream can 
function as a prostate-specific enhancer. Interestingly, the kinetics of the 
receptor binding was different: AR-binding generally peaked at the 60 min 
time point, whereas GR bound in two waves at the 40 min time point and at 
100 min time point. The two-wave-kinetics was seen only at regions ~34 kb 
upstream and ~87 kb downstream, indicative of a role in transcription 
initiation, whereas the other two main binding sites at ~78 kb and ~98 kb 
downstream appeared to be involved in later transcription enhancement. A 
similar delay in binding was seen with AR, but the binding to the initiator 
AREs was of the one-wave type. The importance of the difference in kinetics 
between the receptors remains unclear, but at least the final outcome, i.e. the 
mRNA expression, follows the equal kinetics between the receptors. The 
receptor binding was similarly blocked by the antiandrogen, BIC and the 
antiglucocorticoid, RU486 in LNCaP and A549 cells, respectively, but not in 
VCaP cells overexpressing AR, suggesting that elevated AR levels affect the 
efficiency of the antiandrogen treatment. However, BIC was almost unable to 
recruit RNAPII to the chromatin. 
The chromatin markers were very similar between the cell lines: the total 
H3 levels were decreased, acetylation of H3 and methylation of H3K4 marked 
the TSS and enhancer regions (albeit slightly decreased after 
androgen/glucocorticoid treatment) and H3K36me3 marked the gene body. In 
fact, the histone modifications patterns were very similar to that of genome-
wide data from other cell lines (e.g. B-lymphocyte derived cell line GM12878) 
produced by ENCODE project (genome.ucsc.edu), suggesting that the 
modification patterns of FKBP51 are not restricted only to prostate or lung 
derived cells. RNAPII occupancy mirrored the trimethylation of H3K36 and 
interestingly both of them as well as acetylation of H3 were absent in the 
region unique to the transcription variant 2, further suggesting that variant 1 is 
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the major transcript of the gene. The decrease in H3 density was shown to be 
due to recruitment of SWI/SNF complex to the chromatin in the both cell lines, 
highlighting the importance of ATP-dependent chromatin remodeling in 
FKBP51 regulation. Low ligand effects on H3K4me3 and H3ac together with 
rapid mRNA expression of FKBP51 suggest that the locus is already poised for 
transcription and only minor modifications need to be done after hormone 
treatment. 
Due to close proximity of the C6orf81 to upstream enhancer region of 
FKBP51, the androgen and glucocorticoid responsiveness of the gene as well as 
the responsiveness of 3’-neighboring gene tubby like protein 1 (TULP1) were 
tested. TULP1 did not show any response in either cell line. Interestingly, 
C6orf81 was highly induced by androgens in VCaP cells, but not by 
glucocorticoids in A549 cells even though it has been reported as the GR target 
gene (Reineke et al. 2007). The difference can be explained by poorer GR 
binding and glucocorticoid responsiveness of the upstream enhancer in ChIP 
and RGA, respectively. Surprisingly, in osteosarcoma U2OS-GR cells that have 
been stably-transfected with GR-expression vector, C6orf81 expression was 
induced by glucocorticoids and GR could efficiently bind to the upstream 
enhancer region. This further suggests that the function of the enhancer is cell 
line-specific and the enhancer is important for AR- and GR-mediated 
regulation of C6orf81 (Paakinaho 2010). Another explanation for the 
unresponsiveness of C6orf81 in A549 cells could have been a cell-specific 
insulator between the upstream enhancer and TSS of C6orf81. The binding of 
master insulator protein CTCF and cohesin, an insulator specific binding-
partner of CTCF, were however similar in the two cell lines that was not very 
unexpected, because the CTCF-binding patterns have been shown to be very 
similar between different cell lines (Phillips and Corces 2009, Cuddapah et al. 
2009, Heintzman et al. 2009). The role of CTCF binding on FKBP51 locus may 
be to mediate 3D chromatin interactions instead of insulating the activity of 
enhancers. A model was proposed where CTCF mediates the formation of a 
loop that brings all the AR/GR-bound enhancers into one complex around TSS, 
where they activate RNAPII. 
The old textbook version about gene regulation, where the TFs bind two-
dimensionally to close proximity of the TSSs of genes and activate their 
transcription, have been discredited during last few years. These results 
further support the importance of the 3D-structure of the chromatin in gene 
regulation, especially the chromatin loop formation that is a prerequisite for 
long-range chromatin interactions. The absolute relationship between the 
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found enhancer regions and androgen or glucocorticoid regulation of FKBP51 
or C6orf81 cannot be determined from these present results. Instead, studies 
that clarify the direct interactions between the enhancers and TSS of the gene 
would perhaps provide some hint about the relation, though only disruption 
of the enhancer in vivo would give the final answer. Due to complexity of the 
regulatory regions of FKBP51, the manual 3C would be daunting, but instead 
high-throughput 3C-based methods would be reasonable for that purpose 
(Fullwood and Ruan 2009). In conclusion, these results highlight the emerging 
biological importance of very long-range regulation via distal enhancers by AR 
and GR that should be also taken into account when studying the role of AR in 
PC development. 
5.3 ELEVATED AR LEVELS INFLUENCE THE RESPONSE OF PC CELLS TO 
ANTIANDROGENS (IV) 
The development of drug resistance is a major problem in current PC therapy. 
The role of AR in the resistance is undisputable and several different defects in 
AR action have been reported, such as mutations in AR, ligand-independent 
activation of AR, and overexpression of AR and its coregulators (Heinlein and 
Chang 2004). The overexpression of AR can occur in several ways, but the 
amplification of AR is the most probable alternative (Koivisto et al. 1997, 
Gregory et al. 2001, Linja et al. 2001, Liu et al. 2008). The overexpression of AR is 
thought to sensitize the cells to lower amounts of androgens and this is 
achieved by intratumoral androgen synthesis (Waltering et al. 2009, Mostaghel 
et al. 2007, Montgomery et al. 2008). Furthermore, the antagonist BIC can also 
acquire agonistic properties due to overexpression of AR (Chen et al. 2004). 
Recently established antiandrogens RD162 and MDV3100 are, however, 
resistant to overexpression of AR, probably due to their inhibitory ability for 
AR nuclear translocation (Tran et al. 2009, Scher et al. 2010) (Fig. 13). A limited 
number of cell models for studying the effects of overexpression on AR-
mediated transcription are available. The most widely used PC cell model 
LNCaP has AR expression level equal to normal prostate cells and the receptor 
has a mutation that affects its sensitivity to antiandrogens (Gaddipati et al. 
1994, Veldscholte et al. 1990, Kuil and Mulder 1996, Bohl et al. 2007). The 
recently established PC cell line VCaP possesses most of the common PC 
properties, such as overexpression of AR, derivation from vertebrae 
metastasis, and it has the major gene fusion TMPRSS2-ERG that is found in 
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half of all PCs (Korenchuk et al. 2001, Liu et al. 2008, Tomlins et al. 2005). The 
AR expressed by VCaP cells is not mutated, which is an advantage in studying 
the effects of the overexpression in isolation from the other faults in AR-
mediated transcription. To that end, LNCaP cells expressing normal levels 
were chosen with VCaP cells expressing elevated levels of AR as comparison 
partners in order to study the effects of overexpression on AR-mediated 
transcription by androgens and antiandrogens. 
 
 
 
Figure 13. Chemical structures of selected androgens and antiandrogens. Androgens: T, testosterone; DHT, 
5α-dihydrotestosterone; R1881, methyltrienolone. Antiandrogens: CTA, cyproterone acetate; BIC, 
bicalutamide; RD162. 
 
Initially, the effect of androgens and antiandrogens were examined on AR 
expression. The AR levels were approximately ten times higher in VCaP cells 
than in LNCaP cells both at mRNA and protein levels. After twelve-hours of 
androgen treatment, however the difference had almost completely 
disappeared, though it was still 1.5-fold. The decrease in the difference was 
caused by strong downregulation of AR in VCaP cells and slight upregulation 
in LNCaP cells, suggesting that the autoregulation of AR is not the same in 
these two cell lines, perhaps due to overexpression of TMPRSS2-ERG fusion in 
VCaP cells (Yu et al. 2010). Comparing the accumulation of mRNA by 
increasing R1881 and CTA concentrations revealed that already the basal 
expression level of seven of the nine AR target genes examined was higher in 
VCaP cells, suggesting that overexpressed but apparently unliganded AR still 
possess some residual activity. In fact, abolishing AR by siRNA treatment 
T DHT
BICCTA
R1881
RD162
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decreased the basal expression level of six of the target genes, further 
supporting the notion that unliganded AR has residual, androgen-independent 
activity in VCaP cells. Interestingly, the expression level of the main PC 
diagnostic marker and the most studied AR target gene, PSA was significantly 
higher in LNCaP cells expressing lower levels of AR, whereas expression of a 
highly androgen sensitive gene FKBP51 (II) was significantly higher in VCaP 
cells expressing high levels of AR, further demonstrating that the PSA is a 
rather insensitive AR target gene despite its stature as a model gene. 
Due to T877A mutation in LNCaP cells, a partial AR agonist CTA can 
function as a full agonist (Veldscholte et al. 1990, Kuil and Mulder 1996, Bohl et 
al. 2007). In order to determine whether the overexpressed AR could also 
increase the agonistic properties of CTA, the mRNA accumulation and AR-
binding to the main AREs regulating their cognate genes by R1881 and CTA 
treatment were determined. Interestingly, in both cells, AR target gene 
expression levels were lower when treated with CTA compared to that of 
R1881, but the chromatin binding efficiency of AR was at the same level. These 
results suggest that CTA neither inhibits the nuclear translocation nor DNA 
binding, but the transactivation capability of AR is diminished. Probably due 
to the difference in the AR level, the overall AR binding was higher in VCaP 
cells than in LNCaP cells when comparing the values with samples 
precipitated by a non-specific antibody. The binding efficiency was also well 
correlated to the androgen induction of the target gene mRNAs by R1881 
treatment, but not by that of CTA. Together these data indicate that the AR-
binding affinity can estimate the extent of ligand induction when the cells are 
treated with a full agonist R1881, but not necessarily when treated with a 
partial agonist CTA, even though the AR levels would be overexpressed. 
In contrast to CTA, the T877A mutation in LNCaP’s AR does not have any 
effect on the antiandrogenic properties of BIC (Berrevoets et al. 1993), unlike 
the overexpression of AR (Chen et al. 2004). Opposite to BIC, novel 
antiandrogens RD162 and MDV3100 have been shown to be resistant to losing 
efficacy due to overexpression (Tran et al. 2009, Scher et al. 2010). In fact, it was 
found that RD162 could compete better with R1881 than BIC and it did not 
have any agonistic properties when applied on its own. Instead, it decreased 
the basal activity of some target genes in a similar fashion as siRNA treatment 
against AR, suggesting that it may actively diminish the residual activity of 
overexpressed AR, i.e. it may function as an inverse agonist. The DNA binding 
of AR was also inhibited more efficiently by RD162 than BIC and the BIC-
induced DNA binding was also reflected to the mRNA expression of target 
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genes to some extent. In addition, larger differences between the cell lines were 
revealed by BIC treatments than those of RD162, suggesting that BIC is more 
sensitive to AR overexpression. The differences in DNA binding between the 
cell lines were significantly higher than the differences in mRNA accumulation 
achieved by both antagonists. Even though RD162 was more efficient than BIC 
in decreasing DNA binding of holo-AR, the decrease was only approximately 
50% from the maximum binding, which suggests that the ability of RD162 to 
inhibit DNA binding of AR is sensitive to AR overexpression, but not its effect 
on mRNA expression. 
In conclusion, the development of new therapies for advanced PC is 
problematic because the molecular mechanisms of the drug resistance are not 
fully understood. According to these results and work done with the novel 
antiandrogens, RD162 and MDV3100, one can say that drug development has 
moved one step closer to finding efficacious treatment for PC (Tran et al. 2009, 
Scher et al. 2010). The main advantages of RD162 compared to BIC are that 
RD162 does not induce either target gene expression or DNA binding of AR 
and its competitive inhibition of the receptor is more efficient than that of 
BIC’s. Even though it have been reported that BIC clearly induces AR target 
gene expression in cells engineered to overexpress AR (Chen et al. 2004), the 
present results with more natural VCaP cells overexpressing AR suggest that 
the overexpression per se is not sufficient to convert the antagonist to act as an 
agonist, but other factors are also needed. 
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6. Summary and conclusions 
Prostate cancer is the most common malignancy in western males. The 
development of efficacious therapies is thus very important for public health 
and the national economy. Knowledge about the molecular mechanisms 
underlying the disease is a prerequisite for the development of an efficient 
cure. In this study, these mechanisms were explored taking as an example of a 
few AR target genes and two PC cell lines. 
The role of AR is pivotal in PC development and progression. Thus 
studying the mechanisms of AR action may provide the answers and further 
help to clarify the progression of this disease. The AR-mediated transcription 
has been traditionally studied using only PSA as a model gene. However, it 
was found that PSA is actually a rather atypical AR target gene, since its 
androgen dependency is low and the regulatory regions driving its expression 
are located unusually close to the TSSs. FKBP51 was found to be a highly 
androgen and glucocorticoid-sensitive gene, whose AR/GR-bound enhancers 
are located very distal from the TSS resembling the average SR target gene. 
Moreover, the standard model for PC has previously been the LNCaP cell line 
that does not represent the most common PC type. In this study, the properties 
of the prototype PC cell line VCaP were characterized. These cells overexpress 
AR and have the most common gene fusion, TMPRSS2-ERG, in their genome. 
The AR target genes that mediate the oncogenic properties of AR activity are 
potential drug targets in future PC therapies. The functional implications about 
the role of ELK4 in PC progression and its androgen-dependency have 
inspired others to develop a potential diagnostic method for PC. Encouraging 
information on the superiority of a novel antiandrogen RD162 over the older 
antiandrogens in AR target gene responses was provided. 
In conclusion, novel information about AR-mediated long-range 
transcriptional regulation was discovered. This may have implications about 
which are the important AR target genes in PC progression. In the future, the 
molecular mechanisms involved in the drug resistance should be explored 
intensively, so that the development of novel therapies would be accelerated. 
The use of novel high-throughput genome-wide sequencing technologies, such 
as ChIP-seq and ChIA-PET, may be one way to gain a deeper understanding 
about AR-mediated transcriptional regulation. 
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